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Glioblastoma is the most common adult malignant primary brain tumor with one of the worst 
prognosis. With a survival of 10 to 12 months, glioblastoma remains one of the most challenging 
disease to treat. The standard treatment method involves maximal possible resection of the 
tumor followed by radiation and chemotherapy. However, the short half-life of most 
chemotherapeutic drugs, high systemic toxicity and inability to cross the blood brain barrier 
inhibits effective delivery of the chemotherapeutics to the tumor.  
 
An ideal drug delivery system can reach the tumor site with high efficiency and continuously 
release the drug at the tumor site for an extended period. Adult stem cells including neural stem 
cells (NSC) and mesenchymal stem cells (MSC) have inherent tumor trophic properties 
allowing for site-specific delivery of chemotherapeutics. They can also be genetically 
engineered to secrete the chemotherapeutic drug continuously making them ideal candidates for 
cell-based delivery system for treating glioblastoma.  
 
MSC have been isolated from a wide range of sources including bone marrow, umbilical cord, 
adipose tissue, liver, multiple dental tissues and induced pluripotent stem cells. MSC are also 
easily amenable to viral modification allowing for easy manipulation to produce 
	  
	  
chemotherapeutic drugs. Additionally, more than 350 clinical trials using MSC have 
successfully established the safety of using MSC for cell-based therapies. Collectively these 
factors have led to the widespread use of MSC in cancer therapy. MSC have been successfully 
transduced to produce chemotherapeutic drugs to treat glioma, melanoma, lung cancer, ovarian 
cancer and breast cancer.  
 
Despite the multitudes of advantages that cell therapy provides they are limited in three main 
domains (1) Low cell retention and survival at the site of the tumor (2) In ability to co-deliver 
multiple therapeutics and (3) In ability to deliver drugs other than peptide based drugs. This 
thesis details the work to engineer mesenchymal stem cells to tackle these three issues and 
develop a system that can increase the efficacy of glioblastoma treatment.  
 
To increase the cellular retention and survival we engineered MSC to form multicellular 
spheroids and cell sheets. To co-delivery multiple therapeutics we engineered MSC to form 
MSC/DNA-templated nanoparticle hybrid cluster to co-deliver drugs for cancer therapy. The 
system showed superior performance due to the increased retention of the cells and nanoparticle 
at the tumor site. Finally, to deliver drugs other peptide based we engineered graphene oxide 
cellular patches for mesenchymal stem cells. Graphene oxide can carry diverse therapeutics and 
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Chapter 1. Introduction 
 
 
Glioblastoma, is the most common adult malignant primary brain tumor with one of the worst 
prognosis. With a mere survival of 10 to 12 months, glioblastoma remains one of the most 
challenging disease to treat. Each year more than 23,770 new cases are diagnosed and 16,050 
deaths occur1. The challenge to treating GBM can be attributed to three main reasons (1) the 
highly invasiveness of the cancer precludes complete removal leading to almost 100% 
recurrence rate. In fact, more than 2/3rd of GBM diagnosed are classified to be invasive and 
high grade (III or IV) with less than 54.7% survival2, (2) the blood brain barrier (BBB) prevents 
penetration of most small molecules and macromolecules in to the brain, and (3) the highly 
aggressive nature of the tumor leads to drug resistance further inhibiting traditional 
chemotherapeutic treatment methods (Figure 1). 
 
The current gold standard for treating glioblastoma is a combination of surgery, radiation, and 
chemotherapy. Surgery is the first and the most common line of treatment methods. The 
prognosis however greatly depends on the pathological diagnosis, tumor location, and extent of 
resection. Due to the very nature of the tumor location, the patient is known to lose body 
functions. Despite the latest technological advances in MRI and 3D probing the precise location 
of the tumor before and during the surgery is highly inaccurate further affecting the prognosis 
of the disease.   
 
The second method of treatment is radiotherapy which penetrates deeper into the tissues and 
breaks down the DNA thus killing cells that cannot be removed by surgery. However, the high-
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energy beam has a lot of collateral damage leading to patient discomfort. While, full brain 
radiotherapy can kill most of the tumor cells, in most cases it leads to memory loss. Local is 
more specific with fewer side effects but is not as efficient in killing cells that are far from the 
site of treatment.  
 
The third common treatment protocol is chemotherapy. The BBB however possess a huge 
challenge to getting the drugs into the brain. Temozolomide (TMZ) is the most commonly used 
chemotherapeutic and can increase the average survival from 12.1 months to 14.6 months. 
Systemic delivery of TMZ leads to high levels of accumulation in organs other than the brain, 
and insufficient accumulation at the tumor sites. Local delivery of chemotherapeutics would 
allow the drugs to bypass the BBB and be placed closed to the site of tumor. This would 
potentially reduce the unwarranted side-effects and patient discomfort.  
 
GLIADEL® wafer is an FDA approved extended release carrier placed in the surgical cavity 
after resection for controlled release of the chemotherapeutic drug. GLIADEL® consists of 
carmustine, a chemotherapeutic drug which is encapsulated in polyfebrosan 20 (poly[bis[p-
carboxyphenoxy]] propane and sebacic acid)3. The polymer is biodegradable and breaks down 
through hydrolysis to release the encapsulated drug. The GLIADEL® wafer has shown to 
increase the average survival from 13.1 months to 16.4 months4. GLIADEL® wafer is currently 
prescribed as the second line of treatment, the broader application of GLIADEL® wafer is 
limited by several weaknesses. The drug carmustine that is used has a low half-life (15mins) 
which is too short to diffuse large distance, consequently the concentration of the drug is high 
within 2-3 mm of the wafer and significantly drops after that. The shape of the wafer does not 
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allow intimate contact and the uneven contact leads to uncontrolled hydrolysis, the wafer also 
has shown to cause leakage of cerebrospinal fluid leading to a higher chance of infection. In 
summary, the short-term release and insufficient accumulation of the drug at the tumor site 
makes it unable to kill the residual tumor cells leading to tumor recurrence and failure of the 
carrier system. 
 
An effective cancer therapy would discern cancer cells from normal cells and allow for robust 
killing of the cancer cells only. However most anti-tumor drugs are not specific and 
indiscriminately kill the cells around them. Targeted delivery of these drugs using nanoparticles 
have also not been successful because of masking of the targeting ligands by the biological 
components. Survey of the literature for the past 10 years has shown that only 0.7% (median) 
of the injected nanoparticles penetrate the tumor5. This can be attributed to the high interstitial 
pressure in the tumor vicinity that results in gradients driving fluid away from the tumor center. 
Additionally, the stiff ECM and the hypoxic tumor core limits the amount of nanoparticle 
reaching and penetrating the tumor in glioblastoma. The unfavorable pharmacokinetics, 
difficulty in producing sustained and efficacious concentration in the tumor vicinity, lack of 
selectivity is a few of the reasons why we need to develop a drug delivery system that can 






















Cell-based drug delivery system are a new class of therapeutics that are tumor trophic, has an 
unlimited source of drugs, and can effectively evade the immune system6. Embryonic stem 
cells6, hematopoietic stem cells6, mesenchymal stem cells7, neural stem cells8, and induced stem 
cells9 have been successfully used for cancer therapy. However, the use of embryonic stem cells 
is plagued with ethical concerns, neural stem cells are very hard to source, and induced stem 
cells could become tumorigenic. MSC on the other hand can be obtained from a wide range of 
sources, readily genetically modified, and is tumor-tropic.  
 
Fridenstein first reported MSC merely as proliferating fibroblastic cells from bone marrow 
capable of differentiating into osteoblasts, chondrocytes and adipocytes. Since the advent of its 
discovery, they have been used to treat myocardial infarction10, inflammatory bowel disease11, 
graft-versus-host disease12, type-1 diabetes13, and cancer14. MSC displays strong 
immunosuppressive properties, allowing them to be transplanted without any pre- or post- 
treatment (Figure 2). They are easy to isolate, expand in culture, and have multi-lineage 
differentiation potential and tropism toward neo-angiogenic, tumor, and inflammatory sites. 
MSC also pose no risk of teratoma formation nor are there any ethical issues associated with 
the cell source and are easily amenable to viral modification due to the high amphotrophic 
receptor levels. Standard protocols can lead to 90% transduced cell with no effect on lineage 
differentiation or quality of the progeny. Viral transduction offers long-term stable production 
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efficacy in a clinically relevant glioblastoma 
model and prolonged median survival in 
mice, compared to direct injection of purified 
oHSV83. SC delivery of oncolytic virus has 
proved to be effective in several preclinical 
cancer models, and the challenge is to ensure 
absolute safety of the viral system to avoid 
complications in its clinical translation.
Potentiating stem cell efficacy
Various strategies have been applied to SCs 
to enhance their therapeutic potential (FIG. 2). 
These approaches have been categorized 
with respect to whether they augment intrin-
sic SC properties, function in combination 
with secreted factors to enhance antitumour 
efficacy or improve the delivery of SCs.
Enhancing innate stem cell behaviour. To 
maximize the success of SC-based thera-
pies, it is crucial that they survive in vivo 
until the entire cancer has been eliminated 
and that they successfully migrate towards 
malignancies. Much effort is being spent in 
attempting to enhance these characteristics 
(FIG. 2a). As discussed earlier, allogeneic 
SCs are somewhat immune-evasive but 
are still rejected in an immunocompetent 
recipient, thereby limiting their therapeutic 
potential10. Torikai and colleagues84 used 
zinc finger nucleases to genetically edit 
human leukocyte antigen (HLA) class I 
in ESCs and demonstrated that these cells 
could escape lysis from HLA-restricted 
cytotoxic T lymphocytes. Indeed, the 
rapidly expanding use of genome edit-
ing technologies could be systematically 
applied to create genetically engineered 
allogeneic SCs with improved immune-
evasive capabilities85,86. To prevent immune 
rejection of ESC-derived allografts, 
cytotoxic T lymphocyte-associated pro-
tein 4 (CTLA4)–immunoglobulin and 
programmed cell death 1 ligand 1 (PDL1) 
knock-in human ESCs (hESCs) were cre-
ated to simultaneously disrupt T cell co-
stimulatory pathways and activate T cell 
inhibitory pathways87. Interestingly, neither 
modification on its own conferred immune 
protection to hESC derivatives in vivo, and 
this highlights the necessity of a multifaceted 
approach to immune evasion.
Figure 1 | Using stem cells (SCs) to promote tumour cell death. SCs can 
be modified in various ways to generate antitumour capabilities. a | SCs 
can be engineered to secrete therapeu ic proteins that function directl  on 
tumour cells or indirectly on cells of the tumour microenvironment. For 
example, tumour necrosis factor-related apoptosis-inducing ligand (TRAIL), 
epidermal growth factor (EGF) agonists or interferons (IFNα or IFNβ) can be 
secreted to function on death receptor 4 (DR4) and DR5, EGF receptor 
(EGFR) or IFN receptors (IFNRs), respectively. Alternatively, SCs can secrete 
stromal, immune or blood vessel effectors. b | SCs can be engineered to 
express a suicide gene encoding an enzyme (such as cytosine deaminase 
(CD), carboxylesterase (CE) or herpes simplex virus thymidine kinase 
(HSV-tk)) that converts a prodrug into a cytotoxin. This induces suicide of 
the SC, and cancer cells are killed by the bystander effect, a phenomenon 
that describes the movement of cytotoxin from the SC to adjacent cancer 
cells via a paracrine mechanism or gap junctions. The distant bystander 
effect describes the recruitment of host immune cells in response to death 
or inflammatory signals released from dying cells. c | SCs can be loaded with 
nanoparticles containing chemotherapy or imaging agents that are 
released in the vicinity of the tumour, either passively or in response to 
external stimuli. d | SCs can be infected with oncolytic viruses (OVs). OVs 
replicate within the SCs, which then rupture and release OV progeny that 
can infect cancerous cells and amplify infection. aaTSP1, anti-angiogenic 
thrombospondin 1; IL, interleukin; NK, natural killer; PEX, a fragment of 
matrix metalloproteinase 2.
PERSPECT IVES
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The inherent ability of MSC to migrate towards cancer cells makes them attractive as a cellular 
delivery vehicle for cancer therapy. MSC have been engineered to produce a wide variety of 
cancer therapeutic proteins, such as interleukins (IL-214, IL-1215, IL-1816), interferon-β17, and 
tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) 18. MSC have also been 
engineered to produce prodrug-activating enzymes. In this case, the injection of genetically 
modified cells is followed by administration of the inactive prodrug locally, which is activated 
by the enzyme. This, in principle, would provoke the cell-killing action only at the site 
populated by MSC, minimizing the systemic toxicity. Incorporating a tetracyclin-induced 
promoter to turn off the gene expression confers safety to the transplanted MSC19. Delivering 
oncolytic virus is another popular approach taken for cancer treatment20. These viruses are 
designed to specifically replicate only in tumor cells and amplify only at the target site. While 
there are quite a few oncolytic viruses in clinical trials, their translation is greatly hindered by 
the host immune response and inefficient viral distribution. MSC have been shown to be an 
effective carrier of oncolytic virus in treating ovarian tumors21 and human hepatocellular 
carcinoma22 (Figure 3).   
 
Despite the multitudes of advantages that cell therapy provides they are limited in three main 
domains: 
A.   Low Cell retention and survival at the site of the tumor 
B.   Inability to co-deliver multiple therapeutics 





Specific Aim 1: Low cell retention and survival at the site of the tumor 
 
One of the major challenges with sub cutaneous (SC) is the low retention and survival of the 
cells. Compared to traditional intraparenchymal SC injection >90% of the cells injected onto 
the walls of the GBM resection are lost within 7 days23. A large fraction of the cells is washed 
out by the cerebrospinal fluid or die within the first few hours of injection. The rapid clearance 
of the cells leads to lower efficiency of SC therapy due to insufficient number of cells. 
 
To increase the survival and retention of these cells, biodegradable scaffolds have been 
employed to encapsulate the stem cells. Synthetic extracellular matrix (sECM) encapsulated 
with MSC or NSC placed in the tumor resection cavity have shown increased retention 
translating to increased survival24. The cells were transducer to produce TRAIL protein. The 
sECM allowed for two-fold increase in retention of the cells two week after implantation and 
tumor-selective migration. This led to significant increase in mice survival. Nanofibrous 
scaffold is another strategy used to increase the retention of the cells in the brain23. The 
biocompatibility of the bENS minimizes the toxicity to SC and allows the SC to migrate on the 
matrices.   This method increased the retention in the surgical cavity 5-fold and prolonged 
persistence 3-fold compared to standard direct injection. This resulted in increase of median 
survival from 13.5 days to 31 days in the mice. 
 
Both these methods face serious challenges to clinical translation. The hydrogel uses significant 
mass to fill the cavity and the space occupied by the polymer gets filled up by ECM leading to 
fewer cell-to-cell connections in the resulting tissue25. The initial high in-situ gelation time of 
the polymer also could lead to wash out of the cells. The shielding of the cells by the matrix 
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could lead to lower drug release and increase migratory distance for the cells in the interior of 
the matrix. Finally, the of the polymer could be highly toxic to the brain, and could cause 
immunological reactions, acute rejection, foreign body reaction. We propose to solve the issue 
with low cell retention by engineering the MSC to form (1) Spheroids and (2) Cell sheet.  
 
The second chapter of the thesis discusses the use of these two approaches to solve the issue of 
low retention and survival of the cells at the tumor site. 
 
Spheroids are three dimensional structures formed by aggregation of cells. The larger size and 
presence of ECM in the spheroids would make it less likely to get washed away and help attach 
to the site of injection respectively. Aggregation of MSC to form spheroids has directly 
translated to overall enhancement of therapeutic potential26. The translation of MSC from the 
bench to the clinics has been plagued not just by lower survival and engraftment but also the 
need to excessively expand the cells to get relevant cell number. This leads to increase in 
senescence and lower steamness. MSC in spheroid form has shown to circumvent these issues 
possibly due to the close cell-to-cell contact resulting in higher expression of angiogenic growth 
factors (angiogenin, Fibroblastic growth factor 2, Vascular endothelial growth factor, 
hepatocyte growth factor27-30), C-X-C chemokine receptor 4 (CXCR-4)31, anti-inflammatory 
(TNFa-stimulated gene/protein 6, prostaglandin E226,32), immunomodulatory factors (TGF-ß1, 
IL-633), and steamness factors (Nanog, Sox2 and Oct427,28). The MSC spheroids have also 
shown to better survive under hypoxic conditions that are found in the injured/cancer regions. 
They express more levels of hypoxia inducible factor 1 and manganese superoxide disputes 
which build resistance to oxidative stress induced apoptosis. Finally, they lead to a significant 
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decrease in size (0.25-0.5 of volume of average mono layered cells) which means more cells 
can be injected with the same volume. Preclinical studies using MSC spheroids have shown 
superiority in various models including liver disease34, kidney disease35, ischemic and 
cardiovascular diseases36, wound healing37 and bone and cartilage diseases38,39. MSC spheroids 
thus provides a unique opportunity to be used in cancer therapy to overcome the challenges of 
using MSC.  
 
The second approach to overcome the issues with low cellular retention and survival is to use 
cell sheets. Cell sheets are intact sheets of cells with extracellular matrix, ion channel, growth 
factor receptors and other important cell surface proteins40. Direct implantation of these sheets 
allows for creation of 3D tissue like structure without using any external polymeric materials 
and occupying minimal space in the cavity. Due to the presence of ECM these cells can be 
deposited with minimal loss of cells covering the entire surface. MSC cell sheets have been 
successfully used in various tissue engineering applications such as periodontal tissue41, 
myocardial infarction42, cartilage defects43, bone defects44, fracture healing45, and bone-implant 
interface46. MSC engineered with vascular endothelial growth factor (VEGF) has previously 
been used to create cell sheet for transplantation in ischemic heart failure. The VEGF-MSC-cell 
sheet demonstrated smaller infarct size and remarkable functional recovery due to fewer cell 
death and cell loss.  
 
We hypothesize that both the spheroid and cell-sheet engineered with MSC-TRAIL would lead 
to better therapeutic outcome due to higher survival and retention of the cells. The absence of 
any polymeric material in the system would accelerate the clinical translation of this approach. 
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Specific Aim 2: In ability to co-deliver multiple therapeutics 
 
Cancer is an extremely complex disease involving multiple pathways to evade cell death. The 
cells develop resistance usually due to compensatory signaling pathways and tumor-cell clonal 
evolution under selective pressure of the initial treatment47. Brain tumors in specific, comprise 
of a heterogeneous population of cells and are both genetically and epigenetically unstable. It 
is highly unlikely that any one drug would be able to successfully treat it. Hence it is imperative 
that the drug delivery system is capable to carrying more than one drug type.  
 
The first and the simplest strategy employed to tackle this issue has been to engineer the stem 
cells (SC) to express different therapeutic agents targeting multiple pathways. MSC has been 
engineered to co-express thrombospondin-1 type I repeats (3TSR) which up regulates death 
receptor (DR) 4/5 expression and S-TRAIL which kills the cells by targeting (DR)4/5 receptor 
extending the survival of the mice48. SC have also been engineered to co-express 
immunostimulatory cytokines IL-18 and (IFN)-β to prolong the survival of the rat with 
intracranial GBM 49. The second strategy employed to create bifunctional proteins that can 
attack multiple signaling pathways simultaneously. s-TRAIL fused with EGFR-specific nano 
body expressing SC have shown to significantly decrease the tumor burden and increase its 
survival50. The third strategy is to use an additional agent externally to synergize with SC 
therapy. TMZ a commonly used chemotherapeutic drug has been used in combination with 
MSC expressing TRAIL or interferon-β to increase the effectiveness of the therapy protocol51. 
 
In the first and the second strategy the combination drugs that can be used is limited to peptide 
based drugs. The third strategy exploring diverse therapeutic payloads, the TMZ is administered 
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separately through intravenous infusion. This system is unable to take advantage of the tumor 
trophic properties of MSC and there is no control over the local concentration of the drugs. 
Thus, there is a need to improve the system to be able to deliver a wide range of therapeutics 
and deliver them simultaneously using the same system. 
  
The third chapter in the thesis discusses the approach taken to design and test nanoparticles than 
can be entrapped within the spheroids. We hypothesize that the MSC-Spheroid would carry the 
entrapped nanoparticle to the site of the tumor allowing for site specific release of nanoparticles 
along with continuous release of TRAIL from the engineered MSC. The co-delivery of the drug 
would help eliminate cells that have grown resistance to single chemotherapeutic drugs and 
increase the therapeutic efficacy of the system. 
 
Specific Aim 3: In ability to deliver drugs other than peptide based drugs 
 
Cancer is highly heterogeneous in nature and is constantly evolving. It is highly unlikely that 
any one anti-tumor drug would be successful. Hence, being able to deliver a wide range of 
therapeutics is highly desired for cancer therapy. Drug-loaded NP are usually coupled with 
MSC therapy through either (1) cellular internalization or (2) surface anchorage. Polymeric and 
liposomal based nanoparticles have used MSC to deliver therapeutic cargo through cellular 
internalization. Polymeric nanoparticle such as poly(lactic acid) (PLA), poly(lauryl 
methacrylate) (PLMA) have been used to deliver coumarin-652 and iron oxide53 respectively. 
They have both shown high cellular loading with minimal effect to the viability, proliferation 
and differentiation of MSC. Surface anchorage is another popular method used to load drugs 
onto the surface of the cells. Silica nonorattle carrying doxorubicin have been anchored onto 
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the surface of MSC by specific antibody-antigen recognition54. This composite showed 
increased and prolonged distribution of DOX without affecting the viability and the tumor 
trophic ability. Another popular strategy used to load drugs onto the surface of the cells is to 
employ the streptavidin/biotin interaction. pH responsive nanoparticle carrying docetaxel was 
loaded onto the surface of MSC through this method55. This hybrid material led to decrease in 
the percentage of cancer proliferating cells without affecting the viability and tumor tropism of 
MSC.  
 
However, in case of cellular internalization, the loading efficiency depends on a plethora of 
particle characteristics such as charge, hydrophobicity, size and shape. The stability and 
availability of the drug internalized by the MSC depends on the drug’s ability to escape the late 
endosome, and the effects of the drug within MSC are of concern. In case of surface anchorage, 
the interaction might be short-lived depending on the specific receptor to which they bind. The 
cell also has the potential to turn immunogenic after engineering due to the alteration in 
membrane composition, and the use of the common biotin/streptavidin interaction. These 
methods release the drugs through either exocytosis or simple diffusion making it harder to 
control and predict the release. There is also a high possibility that the cells would excrete the 
drugs before reaching the target site. Hence, there is a need to develop a system that is capable 
of controlled delivery of a wide variety of drugs while taking advantage of MSC’s tumor trophic 
properties for targeted delivery56. 
 
Modified graphene oxide (GO), a 2D graphene sheet functionalized with carboxylic acid, 
epoxide and hydroxyl group has been successfully used in various biomedical applications 
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including bio imaging, gene delivery, drug delivery and tissue engineering57. The high specific 
surface area allows for high drug loading though π-π stacking, electrostatic or hydrophobic 
interaction with small molecules, proteins, and nucleic acid. Sun et al have shown high loading 
of DOX on graphene via adsorption and pH dependent-release58. Since the tumor 
microenvironment is acidic this allows for site-specific release of the drug. While graphene 
oxide is a versatile platform to deliver a wide range of therapeutics with controlled release, the 
low accumulation of graphene oxide at the tumor site is of serious concern for effective 
translation of this technology59 60.  
 
The fourth chapter discusses the approach to combine the drug delivery capability and the 
cellular interaction of GO to load drugs onto the surface of MSC. On one hand, the graphene 
oxide flakes allow for cellular interaction mediated by the hydrophobic interactions, 
electrostatic forces and hydrogen bonding between the GO and proteins from the cell culture 
media, versatility for adsorbing a wide range of therapeutics, and minimal internalization into 
MSC. On the other hand, the tumor-trophic MSC can carry the drug-loaded GO adsorbed on 
the cell surface to the tumor site and ideally the tumor cell, thereby circumventing the issue of 








Chapter 2. Delivery of scaffold free mesenchymal stem 
cells in the tumor resection cavity for treating 
glioblastoma 
 





Most anti-cancer drugs for glioblastoma have poor pharmacokinetics which prevents effective 
translation of the drugs. They usually have short half-life, are unable to cross the blood brain 
barrier and have difficulty producing sustained and efficacious concentration of the drug at the 
site of the tumor. Collectively these factors reduce the treatment efficiency of the drugs. 
 
MSC on the other hand, are multipotent stem cells that are easy to isolate, proliferate, safe and 
allows facile manipulation using genetic engineering techniques. MSC do not express major 
histocompatibility complex (MHC) class II surface molecules, which allows for autologous 
transplantation and absence of any immune rejection issues7. Additionally, MSCs are known to 
have tumor trophic properties and MSC engineered to produce cancer drugs have successfully 
shown potent inhibition of tumor growth61. They release drug at the site of the tumor for an 
extended period. This has allowed MSC to be used in multiple tumor types such as glioma14, 




However, a large fraction of the cells injected are washed out by the cerebrospinal fluid. 
Majority of the cells also dies within the first few hours of injection due to hypoxia, low nutrient 
supply or inflammatory reactions within the target tissue. To increase the efficiency of the 
system, we need to either inject more cells or increase the retention of the cells in vivo. 
However, excessive cell expansion leads to increase in senescence, decrease in 
immunomodulatory properties and lower survival after transplantation. To tackle this issue 
biodegradable scaffold has been used to increase the retention of the cells but, the remnants of 
the polymer could still be toxic and cause immune reaction. 
 
Spheroids are three-dimensional tissue with enhanced cell-cell interaction and closely mimics 
the natural environment. The properties of MSC cultured as a 3D structure is vastly different 
from normal tissue cultured 2D MSC (Figure 4). This could be a result of (1) changing 
polarization of the cytoskeleton and morphology of the cells because of significant 
rearrangement of physical forces within the 3D spheroids64 65. This results in changes in 
substrate stiffness, elasticity, strain and rigidity of the cells influencing the release of paracrine 
factors 66 67, (2) increased cell-cell contact leading to enhanced expression of E-cadherin, N-
cadherin, cadherin 11 and gap junction proteins such as connexin-43 which define lineage 
specificity in MSC 68 69and finally (3) the enhanced extracellular matrix  (ECM) production 
within the spheroids provides a supporting environment for local growth factor and cytokine 
enrichment which supports autocrine signaling 70. 
 
Because of the above-mentioned factors, MSC in spheroidal form have shown to have enhanced 
anti-inflammatory, angiogenic, and stemness factors26. Spheroids also have been found to 
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survive better in ischemic conditions compared to 2D expanded cells71. Additionally, they show 
a downregulation of pro-apoptotic molecules such as Bax 30. These factors are likely to increase 
the survival of MSC in-vivo. The larger size and absence of artificial biomaterial will also 
render the engineered cells less likely to be washed away increasing the therapeutic efficacy 
without additional complications.  In fact, MSC in spheroids have successfully used in various 
pre-clinical models to treat osteochondral disease72, ischemic and cardiovascular disorders73, 
liver disease74, kidney disease 35, wound healing 75, bone 76 and cartilage disease 77. In each of 
these disease models the MSC in 3D spheroid form performed superior to the normal 2D 
cultured cells. They showed increase in cell survival and enhanced engraftment which was 
crucial to the increased efficacy of the system. 
 
Our hypothesis is to inject of scaffold-free multicellular mesenchymal stem cell spheroids 
(MSC-Sph) transduced to produce TNF-related apoptosis inducing ligand (TRAIL) to treat 
glioblastoma (Figure 5). The expected increase in cell survival and retention should translate to 
better treatment efficacy. TRAIL is a chemotherapeutic drug that activates pro-apoptotic factors 
DR4 and DR5 leading to caspase 8 dependent death78. Since the expression of the pro-apoptotic 
factors are much higher in cancer cells compared to normal cells TRAIL preferentially kills the 
cancer cells leaving normal cells unharmed. However, TRAIL has a low half-life (~23-31 mins) 
and is not capable of crossing the blood brain carrier making it an ideal candidate to be delivered 
using MSC18,79,80. GFP-Fluc MSC transduced with Gluc- S-TRAIL (soluble form of TRAIL) 
was detected in vivo for two weeks. Kaplan Meier survival analysis demonstrated a 72- day 
mean survival with MSC-S-TRAIL compared to only 54.5-day survival for MSC GFP in an 























The size of the spheroids greatly affects the viability of the cells, injectability and nutrient 
transport. Traditional platforms such as hanging drop, low attachment plates, membrane based 
aggregation, forced aggregation using centrifugation, membrane based aggregation, magnetic 
structuring are time intensive, labor intensive, have poor standardization and reproducibility, 
are costly and are not amenable to large-scale production 81. Therefore, a scalable and tunable 
bio fabrication process is required for rapid, high throughput, production of spheroids of 
different sizes with good uniformity82. 
 
Microfluidics can be used as a miniaturized high throughput device to generate uniform double 
emulsion droplets. These w/o/w double emulsion droplets are a great compartment to generate 
uniform spheroids83. The outer water layer allows for nutrient and oxygen supply for cell 
growth. Previously this device has been successfully used to rapidly generate uniform MSC 
spheroids. The fluorinated oil (HFE-7500) used as the oil phase allowed for adequate supply of 
oxygen due to its high oxygen permeability. The oil selective permeable barrier also allowed 
for passage of small molecules which encapsulating the cells. The micro-confinement within 
the pico-liter sized droplets in addition to absence of adhesive surface allowed for rapid spheroid 
formation. Compared to the existing protocols which require 1-4 days this device formed 
spheroids within 150 mins.  
 
We propose to use these microfluidic generated MSC-TRAIL spheroids for treatment of 
glioblastoma. To test the system, we generated spheroids of various sizes and measured their 
viability and uniformity. We analyzed the tumor trophic nature of the spheroids, the in-vitro 
21	  
	  
toxicity against glioblastoma cell lines. Finally, we tested the cell retention and therapeutic 






























Figure	  5.	  Mesenchymal	  stem	  cell	  spheroid	  genetically	  engineered	  to	  produce	  TRAIL	  migrating	  









2.1.2 Materials and Methods 
 
Microfluidics device fabrication 
 
The PDMS chips were prepared using soft lithography. Previously manufacture silicon wafer 
with 80 µm in height (SU-8 2150 MichroChem, Newton, MA) was used. The PDMS 
prepolymer and the curing agent was mixed at a weight ratio of 10:1 (Sylgard 184 Silicon 
Elastomer Kit, Dow Corning, Midland, MI). The mixture was thoroughly mixed and the 
generated bubbles were eliminated under vacuum. The prepolymer was added to the silicon 
wafer and cured at 80oC for 45 mins. The inlet and the outlet of the microfluidic chips were 
punched and the chips were bonded to a cover slide using an oxygen plasma for 40 secs at a 
power of 20W (Plasma Asher, Quorom Technologies, West Sussex, and RH).  
 
To create hydrophilic surface in the microfluidic chip surface we used a two-step sol-gel coating 
procedure. The sol-gel solution was prepared by mixing tetrathylorthosilicate (TEOS), 
methyltriethoxysilane (MTES), (heptadecafluoro- 1,1,2,2-tetrahydrodecyl)- triethoxysilane, 
trifluoroethanol and 3-(trimethoxysilyl)-propylmethacrylate at a volume ratio of 2:1:4:1. 
Following this, the sol-gel mixture, methanol, trifluoroethanol and hydrochloric acid solution 
(pH 5.2) was mixed at a ratio of 5:9:9:1 and heated at 85oC for 2 mins. The device was then 
filled with the activated solution using a pipette and heated at 180oC for 2 min. A mixture of 
deionized water (500 mL) acrylic acid (200 mL) ammonium persulfate (10wt%) and 
tetramethylethylenediamine (TEMED) (16mL) was injected into the device at 20 mL/min for 





MSC that was used in the experiments was obtained from Texas A&M Health Science Center, 
Institute for regenerative medicine.  For all the experiments the cells between passage 3-6 was 
used. MSC was cultured using alpha Minimum Essential Medium Eagle (Thermo Fisher 
Scientific) supplemented by 20% FBS and 1% Penicillin Streptomycin (Pen Strep, Thermo 
Fisher Scientific). The cancer cells, U87MG, T98G, LN229, and LN18 were cultured using 
Dulbecco’s Modified Eagle’s Medium supplemented (Invitrogen) by 10% FBS (Atlanta 
Biologics), and 1% Pen Strep. GBM8 was cultured using Neurobasal medium (Thermo Fisher 
Scientific) supplemented by L-Glutamine (Thermo Fisher Scientific), B27 (Thermo Fisher 
Scientific), N2 (Thermo Fisher Scientific), Heparin, Fibroblast growth factor, Epidermal growth 
factor and Pen strep. All the cells used in the study were cultured at 37oC, 5% CO2 and 95% 
relative humidity. 
 
Viral Transduction of the MSC 
 
MSC was transduced with GFP-TRAIL- Lentivirus at varying multiplicity of infection (moi) 
by incubating virions in a culture medium containing 4 µg/mL protamine sulfate (Sigma) and 
visualized under fluorescent microscope for the expression of GFP. MSC with multiplicity of 
infection (MOI) of 10 was used in further studies. All lentiviral constructs were packaged as 
lentiviral (LV) vectors in 293T/17 cells using a helper virus-free packaging system. Lentiviral 
genome (CMVR8.91) was transfected into 293T cells together with an envelope coding plasmid 
(VSVG) and vector constructs. LVs were harvested 40 hours post transfection and concentrated 
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by ultracentrifugation. Titers were determined on 293T cells as transducing units using serial 
dilutions of vector stocks with 8 µg/ml polybrene. 
 
MSC Spheroid generation 
 
The transduced MSC was used to form spheroids using a microfluidic double emulsion device. 
Soft lithography was used to produce two polydimethylsiloxane devices capable of generating 
uniform water in oil and water in oil in water emulsions respectively. The transduced 
mesenchymal stem cells at a density of 5, 10, 20, and 30 million cells/mL was resuspended in 
media containing 0.3% pluronic F-127 (Sigma Aldrich) and 0.7% alginate (Pronova SLG 100). 
This was used as the inner layer. The middle oil layer was prepared using oil phase-based 
surfactant (1% Pico-Surf™). The outer most layer was made from 2.5% pluronic F-127 (Sigma 
Aldrich). The first water in oil droplet was generated in the first chip with a flow-focusing 
design and a channel width and height of 200µm and 150µm respectively. The flow rate for the 
cells and the oil was 2-8µl /min and 8-15µl /min respectively generated using Harvard 
Apparatus PHD 2000 Syringe Pump. The generated water in oil droplets with cells were 
transferred in to the second chip where the pluronic F-127 was introduced at a flow rate of 20-
35µl/min to form water in oil in water double emulsion encapsulating the MSC in the inner 
most layer. The MSC-TRAIL cells formed spheroids within 150 mins. 24 hours after generation 
of the spheroids the double emulsions were added to a filter with pore size of 30-70µm. This 
led to the breaking of the droplet. The filters were then inverted to collect the spheroids and 
used for cancer cell therapeutics. By controlling the inner cell density and the flow rate of the 
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fluids the size of the spheroids can be well controlled to be between 50-150 µm which is within 
the range of injection. 
 
Characterization of MSC spheroid size  
 
Cell spheroids of different sizes were prepared by using three different inner cell densities (106 
cells/mL, 20*106 cells /mL and 30*106 cells /mL). The collected spheroids were imaged under 
bright field microscope. The images were then analyzed using the software image J. 100 images 
per sample was analyzed to measure the size of the spheroids. 
 
Characterization of MSC Spheroid viability 
 
Cell spheroids of different sizes were prepared using three different inner cell densities (106 
cells/mL, 20*106 cells /mL and 30*106 cells /mL). The collected spheroids were stained with 
propidium iodide (Red) (Thermo Fisher Scientific) and Calcein (Green) (Thermo Fisher 
Scientific) to measure the cell viability of the spheroids. Using Image J, the area of live cell 
(Green) was divided by the total area of the spheroids (Red+Green) to determine the ratio of the 
live cell area in the spheroids. 
 
Characterization of MSC Spheroid Migration towards cancer cells 
 
Migration assay was performed using the two-chamber cell culture insert (ibidi). The cancer 
cell U87 expressing mcherry and MSC-Sph (0, 106 cells/mL, 20*106 cells /mL) were plated in 
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adjacent chamber (0.5mm separation) of the cell culture insert at a density of 7500 cells/well. 
The cells were left overnight to attach and the following day the cell culture insert was removed 
to create a well-defined gap of 500 µm. The movement of the cells was captured every hour for 
48 hours using a live cell imaging system. ImageJ software was used to track the individual 
cells for and analyzed using the plugin manual tracking and chemotaxis. 
 
Quantitative real-time PCR 
 
Total RNA was extracted from spheroids of different sizes using Rneasy mini kit (QIAGEN). 
First, the RNA was converted to cDNA through reverse transcriptase (iScript CDNA synthesis 
kit, Biorad). The cDNA was analyzed using real time PCR (SsoAdvanced Universal SYBR 
Green Supermix, BioRad). The relative quantification was performed using the ∆∆Ct method. 
Human GAPDH was used as a control. The primers used for this experiment are the following, 
CXCR4 primer sequence: forward 5′-TCAGTGGCTGACCTCCTCTT-3′, reverse 5′-
CTTGGCCTTTGACTGTTGGT-3′ 
 
In-vitro cell toxicity of MSC-Spheroid 
 
MSC-TRAIL single and spheroid cells were seeded in a 96 well at 10,000 cells/well. The 
condition media was collected after 48hrs. The condition media was added to the U87, T98G 
and LN18 cells that were cultured in 96 well for 24 hrs. The cell viability was measured using 




The MSC-TRAIL single cells and MSC sph were seeded in a 96 well at 10,000 cells/mL. 24 
hours later 10,000 U87 cells transduced with luciferase was added. The viability of U87 cells 
after 24 hours was measured using Steady GLO (Promega) to quantify the amount of luciferase 
produced. The percentage of viable cells was calculated by normalizing to the cells treated 
without TRAIL. 
 
Caspase 3/7 activation pathway analysis 
 
The cancer cells (U87, T98G, LN18) were seeded at 10,000 cells/well in a 96 well. 24 hours 
later the condition media from MSC-TRAIL single and sph was added to the cells. Four hours 
after incubation the caspase 3/7 activation was measured using caspase 3/7 GLO kit (Promega).  
 
TRAIL release from MSC Spheroid 
 
The MSC single cells and spheroids were seeded in a 96 well at a density of 10,000 cells/well. 
The condition media was collected on day 1, 3 and 5 and replaced with equal volume of new 
media. The condition media was analyzed for TRAIL produced using an ELISA kit (R&D 
systems). 
 
Fluorescence guided tumor resection 
 
U87-mC-FL or GBM8 Fluc tumor were harvested at 80% confluency and implanted 
stereotactically (5*10^5 cells) in the right frontal lobe 2 mm lateral to the bregma and 0.5 mm 
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from the dura. Following immobilization on a stereotactic frame mice were placed under an 
Olympus MVX-10 microscope. A midline incision was made in the skin above the skull 
exposing the cranium of the mouse. The intracranial xenograft was identified using mCherry 
fluorescence. A small portion of the skull covering the tumor was surgically removed using 
bone drill and forceps and the overlying dura was gently peeled back from the cortical surface 
to expose the tumor. Under mCherry fluorescence, the U87-mC-FL tumor was surgically 
excised using a combination of surgical dissection and aspiration, and images of mCherry 
fluorescence were continuously captured to assess accuracy of mCherry-guided surgical 
resection. Following tumor removal, the resulting resection cavity was copiously irrigated and 
the skin closed with 7-0 Vicryl suture.  
 
In-vivo therapy using MSC Spheroid 
 
Retention: The U87-RFP tumor was resected as previously described. Following this MSC-
Spheroids transduced with luciferase was transplanted into the post-operative cavity (5*10^5 
cells). The retention of the cells was measured using bioluminescence imaging of MSC. 
 
Survival: The GBM8-Fluc tumor was resected as previously described. Following this either 
the MSC-Spheroids sheet is transplanted into the post-operative GBM cavity (5*10^5 cells). 
The size of the tumor was followed using Fluc imaging. The images were capture on day 3,6, 







The data in the figures are represented by mean and standard error of mean. One-way analysis 
of variance (ANOVA) with the Tukey significant difference post hoc test was performed when 
more than two means were compared. T-test was performed when comparing two means. A 




















2.1.3 Results and Discussion 
 
Characterization of MSC Spheroids  
 
The MSC spheroids were prepared using two microfluidic chips. The first chip (Figure 6B) 
allows for the formation of the first water-in-oil droplet. The single emulsions were fed into the 
second chip (Figure 6C) which is hydrophilic to form the water-in-oil-in-water double 
emulsion. The flow rate of the fluid can be adjusted to form double emulsions of different sizes, 
and different thickness. The cell density can also be adjusted to get spheroids of different sizes 
(Figure 7E). The cells in syringe prior to droplet generation tends to settle down because the 
density of the cell is higher than that of the media. To ensure uniform concentration of the cells, 
we used 0.3% alginate in the inner layer. The viscous gel-like layer prevents the cells from 
settling down and allows for uniform density. The cells formed spheroids within 150 mins. 
Following the formation of the spheroids a cell strainer was used to break and collect the 
spheroids from the double emulsion. Three different cell densities were tested (10*106/ml, 
20*106/ml, and 30*106/ml). The spheroids were uniform in size (Figure 7E) as analyzed using 
ImageJ and had high viability (Figure 7F). This could be a result of the smaller size which does 
not face issues with nutrient transport. The released spheroids were spherical in shape in low 
attachment plates and attached and spread in normal tissue culture plate as previously 
reported83. This demonstrates the rapid, versatile and uniform mass production capabilities of 












Figure	  6.	  (A)	  Microfluidic	  chip	  design	  (B)	  Formation	  of	  water	  in	  oil	  emulsion	  in	  the	  first	  chip	  (C)	  






Figure	  7.	  (A)	  PDMS	  chip	  for	  making	  water	  in	  oil	  emulsion(B)	  Hydrophilic	  PDMS	  chip	  for	  making	  
water	   in	   oil	   in	  water	   emulsion	   (C)	   Uniform	   spheroids	   encapsulated	   in	   double	   emulsion	   (D)	  















































































































Optimizing tumor trophic property of MSC Spheroids 
 
The tumor trophic nature of the cells of MSC allows it to migrate to the site of the tumor for 
targeted cancer therapy84. To optimize the cell spheroids for their migratory capabilities we 
seeded them 500 µm across from the U87 and imaged them for 24 hours (Figure 8). The 
individual cells were then tracked using the plugin Manual J tracker and analyzed using the 
chemotaxis tool. The spheroid formed using 20*106 cells performed the best followed by 106 
cell and single cells.  The spheroids performed better than the single cells in terms of the velocity 
(Figure 10A), distance moved (Figure 10C), directionality (Figure 10B) of the cells towards the 
cancer cells. The directionality is the euclidian distance divided by the accumulated distance. A 
value closer to 1 describes a straight directed motion. MSC when analyzed in the absence of 
tumor cells moved significantly slower and with significantly lower directionality (Figure 9). 
Additionally, the Raleigh test which is a statistical test for directionality was conducted. This 
gave a p-value of 0.277 for MSC without tumor which shows that the cells do not move in a 
common direction. In contrast the Raleigh test for the MSC with cancer cells gave a p-value of 
2.16*10^-7 demonstrating the cells move towards the cancer cells. The CXCR4 gene expression 
was higher in the spheroids compared to the single cells. Since it is a crucial molecule in the 
signaling pathway directing MSC towards the cancer cell, this could be a reason for the 
enhanced migratory properties of the spheroids85 (Figure 10F). For all the future experiments, 







Figure	  8.	  (A)Migration	  of	  MSC	  towards	  U87	  cells	  at	  time	  0hrs	  (B)	  Migration	  of	  MSC	  towards	  
U87	   cells	   at	   time	   24hrs	   (C)	  Migration	   of	  MSC	   Spheroid	   towards	  U87	   cells	   at	   time	   0hrs	   (D)	  





Figure	   9.	  Migration	   of	  MSC	   only	   at	   time	   0hrs	   (B)	  Migration	   of	  MSC	   only	   at	   time	   48hrs	   (C)	  






























































































Figure	  10.	  Comparing	  the	  migration	  capability	  through	  measuring	  velocity,	  directionality,	  




In-vitro therapeutic efficacy of MSC-TRAIL Spheroids 
 
To investigate the therapeutic efficacy of MSC-TRAIL spheroids, we genetically engineered 
MSC to secrete the pro-apoptotic protein TRAIL using lentivirus. The induced cells were used 
to form MSC-TRAIL spheroids. Condition media was collected from the MSC spheroids for a 
week and the amount of sTRAIL released was quantified using ELISA (Figure 11A). The 
amount of sTRAIL released increased over time to 350ng/mL by day 5. There was no difference 
in the amount of sTRAIL released between the single cells and spheroids. When we cultured 
three different glioblastoma cells lines U87, T98G, and LN18 we found only 60%, 23%, and 
24% cells were alive (Figure 11B). There was also no difference between the single cells and 
the spheroids. 
 
The U87 cells that was used was transduced with firefly luciferase. We co-cultured the MSC-
TRAIL with U87 and measured the amount of U87 cells alive after 24hrs by measuring the 
amount of luciferase. We found less than 20% cells alive in both single and spheroid cells 
demonstrating the efficacy of the system (Figure 11C). sTRAIL is known to induce apoptosis 
in the cancer cells through the caspase 3/7 pathway86. The cancer cells grown in normal media 
and condition media from MSC-TRAIL cells were analyzed for the caspase 3/7 activation. We 
found more than 4-fold activation of the signaling pathway in single and spheroid MSC-TRAIL 










Figure	  11.	  (A)	  Release	  of	  sTRAIL	  protein	  from	  MSC	  single	  and	  spheroid	  (B)	  Toxicity	  of	  condition	  
media	  from	  MSC	  single	  and	  spheroid	  (C)	  Toxicity	  from	  co-­‐culture	  of	  MSC	  and	  U87	  (D)	  Activation	  














Figure	   12.	   	   (A)	   Bioluminescent	   measurement	   of	   luciferase	   from	   MSC	   single	   and	   spheroid	  
implanted	  in	  the	  mice	  brain.	  (B)	  .	  Bioluminescent	  image	  of	  MSC	  cells	  injected	  into	  the	  cavity	  of	  













In vivo characterization of MSC-TRAIL Spheroids 
 
To overcome the rapid loss of MSC through direct injection, the spheroid system was designed. 
To determine if the spheroid does last longer than the single cell suspension, we measured the 
persistence of the spheroids and single cells in-vivo transplanted into the GBM cavity. Mcherry 
expressing U87 cells were implanted into the parenchyma of nude mice. After 10 days, 
fluorescence guided surgical technique was used to de-bulk the tumor. The tumor resection area 
was then used to inject either the single or the spheroid cell suspension which expressed GFP 
and firefly luciferase (FL). The number of cells left behind were measured by injecting luciferin, 
the substrate for FL (Figure 12). The spheroid lasted longer when measured on day 18 (p<0.05) 
(Figure 13).  The absence of significant difference on any other days can be attributed to a few 
factors (1) the clogging of the spheroids in the syringe leading to loss of cells before injection 
(2) loss of cells due to puncturing of the brain and subsequent blood loss. 
 
To mimic the GBM treatment on human patients, we investigated the efficacy of MSC-TRAIL 
spheroids on post-surgical GBM in mice. Human derived GBM8 cells, a highly aggressive 
patient derived GBM cell line was implanted orthotopically into the parenchyma of nude mice. 
Fluorescence guided imaging was used to remove the bulk of the tumor after 10 days. The MSC-
TRAIL single and spheroid cells were injected onto the walls of the resection cavity (Figure 
13B). Bioluminescence imaging was performed every three days to measure the size of the 
tumor (Figure 13A). However, the size of the tumor was much larger in the spheroid compared 
to the single cells. This could be a result of the problems mentioned in the previous retention 










Figure	  13.	   (A)	  Quantifying	   the	  bioluminescent	   imaging	  of	  GBM8	  cancer	   cells	  after	   injecting	  
MSC-­‐TRAIL	   single	   and	   spheroid	   cells	   (B)	   Creating	   the	   tumor	   and	   debunking	   to	   create	   the	  














MSC transduced to release TRAIL formed spheroids within the first 4 hours. MSC-
Spheroids also migrated quicker and more efficiently than the single cells due to the higher 
expression of the CXCR4 gene. The transduced spheroids effectively killed the cancer cells 
in vitro. While they showed slight increase in retention in vivo this did not translate to 
effective killing of the GBM8 tumor in vivo. We attribute this failure to the 7µL limit in 
injection into the bran. The low limit allows for clogging of the syringe channel preventing 
the cells from being injected. To circumvent this issue, we plan to test MSC-Cell sheet as 




















Cell sheets are intact sheets preserving the cell-cell interaction, extracellular matrix, nexin, ion 
channels, growth factor receptors, and other cell surface proteins. Since these sheets are 
harvested without trypsin or other proteolytic enzymes there is no cell damage, and loss of 
differentiated phenotypes 87. The scaffold free cell substrate is advantageous because compared 
to single cell injection there is very little cell loss as the sheet easily attaches to the damaged 
tissue site. The cell sheet is also flexible enough to attach to defects that are irregular in shape. 
Unlike biodegradable scaffold, there is no issue of immune reaction, changes in chemistry of 
the material and long in-vivo processing time. Cell sheet have been used to treat cornea, 
esophagus, articular cartilage and periodontal tissue leading to regeneration in a clinical setting 
88 89 90 91. 
 
These numerous advantages of using cell sheet has allowed for its success in treating a wide 
range of diseases such as periodontal regeneration, myocardial infarction, cartilage defects, 
bone defects, fracture healing, bone nonunion, bone-implant interface. In each of these cases 
the cell sheets have outperformed single cell injection due to the increased engraftment, intact 
ECM and non-disruption of surface proteins92. 
 
Genetically engineered cells have also been successfully used to form cell sheet that can 
continuously release the protein of interest for therapy. Genetically engineered cell sheet has 
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been used to treat hemophilia, cornea repair, myocardial infarction. The superior performance 
can be attributed to the enhanced engraftment of the cell sheet suitable for long-term production 
of the protein of interest93 94 95.  
 
One of the earliest and commonly used methods to make cell sheets was developed using 
Poly(N-isopropylacrylamide) (PIPAAm) is a polymer that transitions from hydrophobic to 
hydrophilic at its lower critical solution temperature of 32oC. Typically tissue culture 
polystyrene is coated with PIPAAm and the critical temperature is manipulated to help cell 
attach and detach to form cell sheets. Other methods to create cell sheet includes using vitamin 
C to increase cell matrix production, or using polymerized human fibrin coated dishes wherein 
the intrinsic protease digests the fibrinogen which allows for the cell sheet to readily dissociate 
intact 96. 
 
To solve the issue of cell retention at the tumor site Juli et al used poly (L-lactic acid) (PLA) 
electrospun nanofibrous scaffold (bENS) bearing MSC transduced with TRAIL. The bENS 
based implant increased the retention of the cells five-fold in the tumor cavity. The increased 
retention of the cells directly translated to increase in the median survival of the mice from 13.5 
days to 31 days. While the nanofibrous scaffold is a novel approach to improve the outcome of 
the tumor patient, the biomaterial used could cause immune reaction in-vivo and take a long 
time to be eliminated from the body23.  
 
We propose to use genetically engineered MSC-TRAIL cells to form cell sheet to increase the 
cellular retention and survival in-vivo for GBM therapy (Figure 14). The cell sheet is flexible 
45	  
	  
enough to be placed in an irregular defect such as GBM cavity, the presence of intact ECM 
would make the cells less likely to be washed away and attach to the tumor site easily. Unlike 
the electrospun scaffold there are no external biomaterial in this system that could cause 
immune reaction.  
 
We have optimized a previously used method developed in our lab to produce cell sheets. The 
cells are cultured on collagen coated poly(dimethysiloxane) under low oxygen (2%) and with 
ascorbic acid. The collagen allows for the cells to adhere to the PDMS surface, the low oxygen 
allows for rapid growth of MSC and the presence of ascorbic acid in the growth media causes 
robust ECM production. The cell sheet that is formed is easily detached or fused with other cell 
sheets by rolling together. This method offers a robust protocol to manufacture cell sheets of 
different thickness with limited in-vitro processing.  
 
To test our system, we used MSC-TRAIL cells to create cell sheets. These cell sheets were 
fused together to increase the thickness and fused cell sheets were punched using a biopsy 
puncher to give cell sheets of different sizes. The cell sheet was tested for sTRAIL production, 















Figure	  14.	  MSC	  Cell	  sheet	  engineered	  to	  produce	  TRAIL	  implanted	  in	  the	  tumor	  resection	  cavity	  








2.2.2 Materials and Methods 
 
 
Manufacturing MSC Cell sheet 
 
The PDMS substrate used to culture the MSC was oxygen-plasma treated (Trion Phantom II 
Reactive Ion Etcher) for 60s, 300mTorr chamber pressure, 20cm3 O2 flow rate, and 20W RF 
power. Plasma-treated substrates were immediately immersed in sterile EtOH for sterilization, 
and then coated with rat tail collagen I (Sigma-Aldrich, Germany) at 15mg/cm2 for 1h to 
facilitate MSC attachment.  
MSCs below passage 5 were seeded at 10,000cells/cm2 on collage coated, PDMS substrates and 
cultured using complete media [α-minimum essential medium (Gibco) with 20% fetal bovine 
serum (Atlanta Biologicals), 1% penicillin/streptomycin (Life Technologies, Rockville, MD), 
and 82.5µg/ml L-Ascorbic acid (Sigma-Aldrich)] at 37°C in a hypoxic chamber of 5% O2 for 
3 weeks. To create a tubular vessel structure using hMSC sheets, confluent hMSC layers were 
carefully detached from the PDMS with tweezers and wrapped onto a temporary supporting 
mandrel (teflon rod, 1mm diameter). Two to four MSC sheets were rolled around a mandrel. 
These sheets were allowed to fuse in complete media inside hypoxic chamber overnight. For 
further maturation of the cellular assemblies, the cell sheets with the mandrel were incubated in 
the hypoxic incubator of 5% O2 for 2 weeks. The fused cell sheets were cut and open and a 





Cell viability of the cell sheet 
 
The cell sheet of different thickness was labeled with propidium iodide (Thermo Fisher 
Scientific) and calcein (Thermo Fisher Scientific). The cell sheet was imaged using a 
fluorescent microscope. 
 
Migration of MSC cell sheet towards cancer cells 
 
Migration assay was performed using the two-chamber cell culture insert (ibidi). The cell sheet 
was placed on the 24 well plate and spun down at 500 rpm for 5 mins to allow them to 
momentarily attach to the plate. In one of the inserts 7500 cancer cells were plated (U87 MG). 
500 mL of media was then added to the plate and allow to attach overnight. Next day the insert 
was removed to create a well-defined gap of 500 µm. The movement of the cells was captured 
every hour for the next 120 hours using a live cell imaging system at 37o C, 5% CO2.  
 
sTRAIL release from MSC-TRAIL Cell sheet 
 
The cell sheet prepared using MSC-TRAIL cells was plated in a 48 well plate with different 
diameters (3.5mm and 5mm). The condition media was collected on day 1, 3, and 6 and replaced 
with equal volumes of new media. The condition media was analyzed for TRAIL production 
using an ELISA kit (R&D systems) to measure the protein levels. 
 




The cell sheet prepared using MSC-TRAIL cells with different diameters (3.5mm and 5mm) 
were plated in a 48 well plate. They were allowed to attach overnight. Following this 10,000 
cells/well of U87MG and GBM8 transduced with luciferase were added. 24 hours following 
co-culture the viability of U87MG and GBM* was measured using the steady GLO (Promega) 
to quantify the amount of luciferase produced. The percentage of viable cells was calculated by 
normalizing luciferase signal to that of the cells cultured without MSC-TRAIL cell sheet. 
 
Fluorescence guided tumor resection 
 
U87-mC-FL were harvested at 80% confluency and implanted stereotactically (5*10^5 cells) 
in the right frontal lobe 2 mm lateral to the bregma and 0.5 mm from the dura. Following 
immobilization on a stereotactic frame mice were placed under an Olympus MVX-10 
microscope. A midline incision was made in the skin above the skull exposing the cranium of 
the mouse. The intracranial xenograft was identified using mCherry fluorescence. A small 
portion of the skull covering the tumor was surgically removed using bone drill and forceps and 
the overlying dura was gently peeled back from the cortical surface to expose the tumor. Under 
mCherry fluorescence, the U87-mC-FL tumor was surgically excised using a combination of 
surgical dissection and aspiration, and images of mCherry fluorescence were continuously 
captured to assess accuracy of mCherry-guided surgical resection. Following tumor removal, 





In vivo retention of MSC Cell sheet 
 
Retention: The U87-RFP tumor was resected as previously described. Following this MSC-Cell 
sheet transduced with luciferase was transplanted into the post-operative cavity (5*10^5 cells). 
The retention of the cells was measured using bioluminescence imaging of MSC. 
 
In vivo survival using MSC-TRAIL cell sheet in an intracranial tumor model 
 
Survival: The GBM8-Fluc tumor was resected as previously described. Following this either 
the MSC cell sheet is transplanted into the post-operative GBM cavity (5*10^5 cells). The size 
of the tumor was followed using Fluc imaging. The images were capture on day 3,6, and 11 to 




The data in the figures are represented by mean and standard error of mean. One-way analysis 
of variance (ANOVA) with the Tukey significant difference post hoc test was performed when 
more than two means were compared. T-test was performed when comparing two means. A 







2.2.3 Results and Discussion 
 
 
Characterization of Cell sheet 
 
a.   Preparation 
Figure shows the overall scheme for bio fabricating the cell sheet. The cell sheet was grown 
under hypoxic condition as it has been shown to increase the MSC viability and multipotency 
97. Ascorbic acid was also added to the MSC culture to increase the ECM production and allow 
for faster cell sheet formation 98. Two or four cell sheets from the PDMS mold was wrapped 
around a mandrel and allowed to fuse for an additional 3 weeks (Figure 15).  
 
b.   Viability of the cell sheet 
The MSC cell-sheet fused with 2 and 4 sheets were analyzed for toxicity using propidium iodide 
staining. The 4-sheet cell-sheet showed higher cell death, which could be a result of reduced 
transport within the multi-layer cell sheet or the longer incubation time needed for fusion. 
Therefore, for all future experiments the cell sheet fused with 2 layers were used (Figure 16).  
 
c.   SEM characterization 
The prepared cell sheet was analyzed under SEM and the cross section and longitudinal sections 
of the cell sheet clearly demonstrates multiple layers of the vessel wall with confluent cell 




























































































































Figure	  16.	  Live	  Dead	  staining	  of	  MSC	  cell	  sheet	  with	  (A)	  4	  layers	  (B)	  2	  layers.	  Scanning	  Electron	  



















Figure	  17.	  (A)	  MSC	  cell	  sheet	  (green)	  migration	  towards	  cancer	  cell	  U87	  (red)	  at	  0	  hrs	  (B)	  MSC	  

























Migration of MSC Cell sheet towards cancer cells 
 
While the MSC-Cell sheet implanted in the GBM cavity can kill the residual cells by 
continuously releasing sTRAIL, we also wanted to investigate the ability of the cells to leave 
the cell sheet to target invasive glioblastoma cells that have penetrated the contra lateral 
hemisphere. The cell sheet and U87 cells were plated in a 24 well with a well-defined gap of 
500um between them. The cells were imaged for a total of five days. The cells started moving 
out of the cell sheet towards the cancer cells after 48hrs and moved towards the cancer cells by 
120 hrs (Figure 17). This shows that the cells are also capable of tracking the distant tumor cells, 
which is critical for complete elimination of the tumor. 
 
Therapeutic efficacy of MSC-TRAIL Cell sheet in vitro 
 
To investigate the therapeutic efficacy of the system in-vitro, we created MSC-cell sheet using 
TRAIL induced cells. The cell sheet was punctured with a biopsy punch in two different sizes 
(3.5mm and 5mm). The condition media from the cell-sheet was collected on days 1,3, and 5. 
The amount of sTRAIL produced was calculated using an ELISA kit for TRAIL protein (Figure 
18). The amount of TRAIL increased with time, with 5mm cell sheet producing 255ng/mL 
sTRAIL compared to 53ng/mL sTRAIL by the 3.5mm cell sheet. The cell-sheet was also co-
cultured with two different GBM cell types (U87 and GBM8). 24 hours later the cell viability 
was measured using cell-titre GLO. The larger cell sheet lead to more cell death in the case of 










Figure	  18.	  Characterization	  of	  MSC	  Cell	  sheet.	  TRAIL	  release	  from	  cell	  sheet	  with	  (A)	  3.5mm	  
























































































































MSC-TRAIL killing the 
remaining cancer cells
Figure	  19.	  In-­‐vivo	  plan	  to	  investigate	  the	  cellular	  retention	  and	  survival	  of	  MSC	  cell	  sheet	  in	  a	  





MSC-TRAIL cell sheet offers an alternative method to increase the cell retention and survival. 
The cell sheet allows for implantation in an irregular cavity such as GBM. The presence of 
ECM and strong nature of the cell sheet prevents the cell from dying and being washed out on 
implantation. The cell sheet was shown to migrate towards the tumor cell, single cells also 
migrated out of the tumor which could target long distance GBM cells. The MSC-TRAIL cell 
sheet released sTRAIL constantly over a period of a week and led to effective killing of GBM 
cells in-vitro. We hope to test the retention and therapeutic efficacy of the cell sheet in-vivo in 
















Chapter 3. MSC/DNA-templated nanoparticle hybrid 





The complex evolutionary nature of cancer has limited the efficacy of chemotherapy due to the 
inevitable development of resistance. There are various molecular mechanisms that have been 
implicated in tumor resistance, the increased rate of drug efflux, alterations in drug metabolism, 
and mutation of drug targets. The resistance is generally developed either through activation of 
compensatory signaling pathways or development of clonal evolution under the selective 
pressures of treatment. Tumors are known to be highly adaptable and often during treatment 
activate survival signaling pathways or inactivate downstream death signaling pathways often 
rendering chemotherapy ineffective. Tumors are also highly heterogeneous in nature and 
contain molecular and genetic heterogeneity which often leads to drug resistance through 
therapy induced selection of resistant subpopulation that was originally part of the tumor. The 
presence of cancer stem cells has also been implicated as a path to developing resistance to the 
chemotherapeutic drugs. Thus, it is inevitable that a combination of drugs will be needed for its 
elimination 99 100 101. 
 
The concept of delivering more than one drug for treatment is not a new one; it has long been 
recognized that using two drugs with complementary effects can achieve a better result than the 
use of a single drug. However, the advantages of combination therapy can easily become 
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nullified if the effects of both drugs are not experienced by the same cell. This is where co-
delivery steps in, offering a carrier system that will deliver both therapeutic agents to the same 
cell, at the same ratio of loading, thereby ensuring the effectiveness of the combination therapy. 
Synergism in the context of co-delivery is typically identified as an increase in the level of the 
desired therapeutic effect when compared with delivery of only one drug, or when compared 
with the effect of the two drugs delivered in combination, but separately. To gain the optimal 
synergistic impact, cargo can be strategically chosen to exert a desired mechanistically-based 
synergistic effect on the target. Traditionally co-delivery has been achieved using well-
established liposomal, dendrimer, polymeric, and nanoparticle systems, as well as more 
unconventional carriers such as Janus particles and DNA nanogel. However, the issue of poor 
targeting and pharmacokinetic discussed previously necessitates the need to develop cell based 
carriers for dual delivery of drugs102.  
 
The inherent tumor trophic ability of MSC has made them an attractive cellular delivery vehicle 
for cancer therapy6,7,103. While engineered MSC have shown promise in treating cancer, 
monotherapy has not proven effective in treating highly heterogeneous cancer. Additionally, 
cancerous cells gain resistance to chemotherapy during their evolution, prompting the need for 
combination therapy. For example, TRAIL-engineered MSC delivered alongside temozolomide 
was more effective in treating glioblastomas than either of the individual therapies104. However, 
to make sure that both the drugs reach the tumor site simultaneously, MSC have been 
engineered to secrete bispecific molecules such as, CD20 specific single chain Fv antibody 
fused to TRAIL (scFvCD20-TRAIL105). The combination was more efficient than delivering 
TRAIL-transduced MSC alone for treating non-Hodgkin’s lymphoma because of the 
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simultaneous inhibition of proliferation and induction of apoptosis in cancer cells by targeting 
CD20 and DR4/5. ENb-TRAIL is another such bispecific molecule that targets endothelial 
growth factor receptor (EGFR) and DR4/5 simultaneously that showed superior efficiency50. 
 
Despite wide range of benefits provided by MSC for cancer therapy, MSC can deliver only 
protein based drugs. In most cases MSC is genetically transduced to produce interleukins, 
interferons, prodrugs or TRAIL15,106,107. To deliver small molecules and nucleic acid based 
drugs, the drugs are usually loaded through (a) cellular internalization or (b) surface 
modification. However, both methods face serious challenges. In case of cellular 
internalization, the internalized drug could adversely affect the properties and viability of MSC. 
The drugs in this case is released through exocytosis where the release cannot be controlled and 
could lead to premature release of the drugs. In case of surface modification, the interaction is 
usually short lived and could cause the cells to become immunogenic due to the change in 
membrane structure52,56,108-110. Simply delivering the nanoparticle alongside MSC also does not 
serve its purpose, because less than 0.7% of the injected nanoparticle has been shown to 
penetrate the tumor site. Hence, there is a need to develop a system that can co-deliver diverse 
therapeutics simultaneously.  
 
We propose to design nanoparticles than can be entrapped within the spheroids (Figure 20). We 
hypothesize that the MSC-Spheroid would carry the entrapped nanoparticle to the site of the 
tumor allowing for site specific release of nanoparticles along with continuous release of TRAIL 
from the engineered MSC. The co-delivery of the drug would help eliminate cells that have 
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grown resistance to single chemotherapeutic drugs and increase the therapeutic efficacy of the 
system. For this we have selected TRAIL and Mitoxantrone (MTX) as model drugs. 
 
Apoptosis in cells is caused either through the extrinsic or the intrinsic pathway. TRAIL is a 
protein that is known to causes apoptosis without any noticeable side effects in a wide range of 
cancer cells through the extrinsic pathway. The TRAIL protein binds to the death receptors 
(DR4/DR5) on the surface of the cancer cells. This allows for the formation of the death 
inducing signaling complex (DISC) which recruits the Fas-associated protein with the death 
domain (FADD). FADD recruits pro-caspase 8/10 which leads to activation of downstream 
substrates that are implicated in the apoptotic pathway 78.  
 
TRAIL has shown considerable promise in treating a wide range of cancer cells including lung 
cancer, breast cancer, squamous cervical cancer, lung metastases, renal cell carcinoma and 
malignant fibrous histiocytoma 111 112 113. However, the short-half life, inadequate delivery 
methods and development of resistance has prevented it from clinical translation 79 80. To 
overcome the short half-life issue, TRAIL has been modified with PEG 114, delivered using 
virus 115, loaded onto nanoparticles 116 and delivered using stem cells18. Stem cells has shown 
the highest promise to deliver TRAIL due to the continuous release of drug near the tumor site. 
However, nearly 20% of the cancer cells tested against TRAIL were resistant or developed 
resistance during the evolution of the tumor 117. The resistance to TRAIL develops at every 
level of the TRAIL signaling pathway from ligand binding to effector caspases. Since TRAIL 
initiates cell death through the extrinsic p53 independent pathway, combination therapy with 
TRAIL has found the highest success by combining it with p53 dependent intrinsic pathway 
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such as chemotherapy or radiation. This usually leads to augmentation of the apoptotic signal 
produced by the cancer cells and elicits enhanced apoptosis and in some case reversal of the 
resistance. 
 
Mitoxantrone (MTX), on the other hand is a synthetic anthracenedione and is routinely used in 
the treatment of breast cancer, lymphomas, prostate cancer and leukemia 118 119 120 121. MTX 
causes cell death through the intrinsic apoptotic pathway. MTX is a DNA topoisomerase II 
inhibitor which, inhibits DNA synthesis by intercalating with the DNA, inducing DNA strand 
breaks by stabilizing the topoisomerase-DNA cleavable complex and causes DNA aggregation 
and compaction all leading to cell death. However, its translation is limited due to acute toxicity, 
development of cell resistance, and inability to cross the blood brain barrier. Some of the side 
effects of MTX include nausea, vomiting, cardiotoxicity, leucopenia, stomatitis which limits 
the intravenous dose 122 123. The resistance is usually a result of increased p-glycoprotein 
expression or increase in compensatory DNA repair mechanism. Combination therapy using 
TRAIL and MTX can overcome the issue of resistance by targeting both the intrinsic and 
extrinsic apoptotic pathway 86. To achieve this TRAIL will be delivered using MSC and the 
MTX will be carried using a nanoparticle. 
 
A nanoparticle (NP)-formulation may prevent the potential side effect and enhance the drug 
delivery efficiency. For example, polybutylcyanacrylate (PBAC) NP-formulated MTX is now 
in clinical trial and the phase II results for treating hepatocellular carcinoma shows prolonged 
median survival on PBAC NP-treated patients 124 (1). Reszaka et al., also tested the 
biodistribution of free MTX, liposomal and polybutylcyanoacrylate (PBAC) NP-formulated 
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MTX in a preclinical melanoma model. Although PBAC NP formulated MTX holds similar, 
better drug accumulation on the tumor site, the interaction between PBAC and MTX is 
relatively low; due to the weak interaction between PBAC and MTX, 90% of the drug is 
released right after the administration 125, which may also explain why leucopenia is still the 
major (47.4%) complication of the patients in the hepatocellular cancer trial 124. To resolve this 
loading issue, instead of common liposome and polymeric NP formulations, we chose DNA as 
drug loading carrier for this application. Anthracenedione drug is known to hold high affinity 
against DNA 126, and this DNA-drug interaction has been widely used to deliver 
anthracenedione drugs 127,128 129. High loading efficiency is the major advantage of this 
approach, but simple naked DNA may be not efficient on cell internalization nor tolerant again 
serum nuclease. Calcium phosphate (CaP) precipitation is a way to form a DNA-structured NP.  
 
However, conventional NP formation using CaP precipitation is hard to control particle size 
and stability, resulting in low transfection efficiency and high batch-to-batch variation. Several 
approaches, such as co-precipitation with an anionic polypeptide 130 131or nucleic acid-
PEGylation 132, have been reported to improve the DNA-structured NP production and 
performance. Inspired by these approaches, we design a series of PEGylated DNA structures, 
which can control the NP size, cellular uptake and surface ligand coverage via CaP 
precipitation. By tuning the PEG length and conjugating a brain tumor specific ligand, we could 
reduce the cell uptake on MSC side and maximize the drug delivery efficiency to the tumor site. 





To further increase the targeting nature of the system we propose to decorate the nanoparticle 
surface with IL13RA2 ligand. Interleukin 13 (IL13) plays a major role in regulating the immune 
response and immune microenvironment. Interleukin 13 receptor subunit alpha 2 (IL13RA2) is 
a membrane protein that binds to IL13 with low affinity trigger downstream signaling 
processes133. In cancer cells this affinity is high. In fact, IL13RA2 is sparsely expressed in 
normal tissue and increases to 30,000 binding sites for IL-13 per cell in glioma134,135. Taken 
together, these factors make IL13RA2 an efficient targeting ligand for treating glioblastoma. 
Baoyan Wang et al created pep-1 a peptide which specifically binds to IL13RA2 and can cross 
blood tumor barrier and home to glioma136,137. Pep-1 conjugated PEG-PLGA nanoparticle 
showed significantly enhanced cellular association and 2.21 times higher distribution in an 
intracranial glioma model. Pep-1 decorated nanoparticle loaded with paclitaxel and increased 
the median survival time from 23 days without ligand to 32 days with the targeting ligand. 
 
To create this Spheroid-NP hybrid system, double emulsion based microfluidic method was 
used. MSC transduced to produce TRAIL was mixed with nanoparticle carrying MTX and 
loaded onto the microfluidic platform to create uniform double emulsions. The cells and 
nanoparticle in the tiny volume have no surface to attach onto and is forced to aggregate to form 
the spheroids carrying the nanoparticle.  
 
The MTX, TRAIL drug combination was tested against a wide range of glioma cell lines to 
optimize the concentration to achieve maximal synergy. The concentration chosen, showed a 
large therapeutic index demonstrating that it can be loaded onto MSC and can kill cancer cells 
leaving MSC unharmed. The MSC-Sph-NP was visualized under confocal microscope and the 
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nanoparticle was found to be evenly distributed throughout the spheroids with partial uptake 
and the rest in the ECM of the spheroids. The MSC-Sph-NP also showed viability >75% when 
tested using flow cytometry. The migration of MSC-Sph-NP towards cancer cells showed that 
the cells can carry the nanoparticle to the site of tumor without reducing its tumor trophic nature. 
MSC-Sph-NP was superior in its killing of glioma cells in-vitro compared to MSC-Sph and 
MSC-Sph-MTX. Finally, in-vivo U87MG tumor model showed increased retention and 
survival of both the Spheroids and nanoparticle in the MSC-Sph-NP group compared to the 
single cells with NP. This significant improvement also translated to better therapeutic efficacy, 
the tumor volume of the MSC-Sph-NP was significantly smaller than the Single-MSC-NP and 




























Figure	   20.	   MSC	   NP	   hybrid	   spheroids	   migrating	   towards	   the	   tumor	   site	   and	   releasing	  




3.2 Materials and methods 
 
 
Evaluating the chemotherapeutic effect of TRAIL and MTX 
 
The cancer cells (U87MG, T98G, LN229, LN18 and MSC) were seeded at a density of 10,000 
cells/ well in a 96 well plate. 24 hours after plating the cells were exposed to different 
concentrations of MTX (0.2-100 µg/mL) (Sigma Aldrich), TRAIL (0.00625-3.2 µg/mL) 
(Thermo Fisher Scientific) and a combination of MTX+ TRAIL (0.15 µg/mL TRAIL and 0.2-
100 µg/mL MTX). 24 hours following the exposure to the drugs Cell GLo 3D (Promega) 
substrate was added at 1:1 ratio with the media to the cells and incubated for 30 mins and the 
luciferase signal was measured using the Fluostar optima plate reader. The cell viability was 
calculated using the luciferase signal assuming 100% viability in the case of no drug.  
 
Nanoparticle generation and characterization 
 
The amine-functionalized PEGylated-DNA structures were synthesized using Click chemistry. 
Briefly, the reaction was carried out in 200 mM trithylamiimum buffer (pH 7) containing 50% 
dimethyl sulfoxide (DMSO) with single-stranded DNA (50 µM), amine-PEG-azide (250 µM), 
L-ascorbic acid (10 mM) and copper(II)-TBTA complex (500 µM) in an argon atmosphere for 
overnight at room temperature. The product was then purified by reversed-phase HPLC and 
then lyophilized. Pep1, the anti-IL13RA2 peptide with a N-terminal acetamidomethyl 
protection group was synthesized by Peptide 2.0 Inc. (Chantilly, VA). For the Pep1 conjugation, 
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amine-functionalized PEGylated DNA structures were first activated by 10-fold of 
sulfosuccinimidyl 4-(N-maleimidomethyl)cyclohexane-1-carboxylate in PBS at RT for 2 hours. 
Excess crosslinkers were removed by a MWCO 10k ultracentrifugation column, and the 
activated linkers were subsequently incubated with Pep1 for overnight at 4oC. Prior to the drug 
loading, Pep1-PEG-DNA products were purified by the MWCO column to remove unreacted 
Pep1, and Pep1 was reduced by tris(2-carboxyethyl)phosphine at RT for 1hr. For drug loading, 
MTX was loaded onto the DNA structure (containing 25 % of Pep1-PEG-DNA and 75% of 
PEG-DNA) through a gradient-annealing process. Drug-loaded micelles were formed by 
mixing with a Ca2+ containing Tris-EDTA buffer (pH = 7.6). The resulted micelle size was 
around 150 nm in diameter with a monodispersed PDI (<0.1). In order to remove the Ca2+ ions 
in the solution for MSC spheroid formation, the micelles were then buffer-exchanged and stored 
in 0.9 % saline solution.  
 
Expression of IL13RA2 on the cancer cell surface 
 
a.   Flow cytometry 
U87, LN18, and GBM8 cells were seeded in a 24 well plate overnight. The cells were 
trypsinized and spin down and stained with Human IL-13 R alpha 1 fluorescein-conjugated 
antibody (R&D systems) at a concentration of 10 µL/106 cells and incubated for 30 mins in the 
dark. The unbound antibody was washed using the flow cytometry staining buffer. The sample 
was suspended in the 200 µL of the washing buffer for analysis. All stating procedure was 
performed in ice. The sample was analyzed using the BD FACSCanto flow cytometry and 




b.   qPCR 
Total RNA was extracted the cancer cells (U87MG, LN18, GBM8) using the Rneasy mini kit 
(QIAGEN). First, the RNA was converted to cDNA through reverse transcriptase (iScript 
CDNA synthesis kit, Biorad). The cDNA was analyzed using real time PCR (SsoAdvanced 
Universal SYBR Green Supermix, BioRad). The relative quantification was performed using 
the ∆∆Ct method.  
 
Generation of MSC-Sph-NP 
 
MSC (20*106 cells/mL) was mixed with DNA-structured NPs ([total PEGylated DNA] = 
9.4µM; generated by mixing with calcium-containing Tris buffer and buffer exchanged using 
Sephadex G-25 column) in a in a solution of 0.7% alginate, 0.3% PF127. The mixture was 
loaded onto the microfluidic platform to generate spheroids encapsulating the nanoparticle. The 
first hydrophobic chip had a flow rate of 6-8 µL/min for the oil layer and 4-6 µL/min for the 
inner cell layer. The second chip a flow rate of 20 µL/min with 2.5% PF127 as the outer fluid. 
The double emulsions encapsulating the cell and nanoparticles were cultured for 24 hours at 
37oC, and 5% CO2. Following this, the spheroids were released from the double emulsion using 
a filter. The emulsions on exposure to air breaks apart and releases the spheroid which was 
collected by inverting the filter 
 
 




a.   Confocal imaging 
The MSC cell membrane was labeled with PKH26 (Sigma Aldrich), and the nanoparticle was 
labeled with Alexa Flour 647 (Thermo Fisher Scientific). The combination was used to generate 
MSC-Sph-NP as described previously. 24 hours after the formation the spheroids were released 
and imaged using a confocal microscope. 
b.   Cell viability of MSC Spheroid-NP FACS 
The viability of MSC-NP-Sph loaded with TRAIL and MTX was measured using the Dead cell 
apoptosis kit with Annexin V Alexa Flour 488 and Propidium Iodide (Thermo Fisher 
Scientific). Briefly the cells were harvested and washed in cold PBS. The cells were then 
resuspended in 5µL of AlexaFLour 488 Annexin V and 1µL of 100µg/mL of propidium iodide 
and incubated for 15 mins. An additional 400µL of annexin binding buffer was added and the 
sample was placed on ice before analysis. The fluorescence intensity was measured at 530nm 
and 575nm using an excitation of 488nm. 
 
Nanoparticle distribution in the spheroid 
 
To verify if the DNA-structured NP was internalized by MSC, we labeled both the DNA part 
with a FITC and the PEG part with Alexa Flour 647. When the PEG-DNAs form a NP, the 
FITC fluorescence would be quenched due to the self-quenching effect taking place inside NP. 
If the MSC internalizes the NP, NP degradation in MSC would rescue the FITC fluorescence 
because of the DNA release. In this case, both FITC and Alexa Flour 647 signals could be 
observed. In contrast, if the NP is only associated on MSC membrane or in ECM, intact NP 
72	  
	  
would not emit FITC signal, and only Alexa Flour 647 signal could be detected. This cell uptake 
analysis was carried out in both 2D culture and in the 3D spheroid form. 
 
Characterization of MSC-Sph-NP migration towards cancer cells 
 
Migration assay was performed using the two-chamber cell culture insert (ibidi). The cancer 
cell U87 expressing mcherry and MSC-Sph-NP (MSC engineered to produce GFP and 
Nanoparticle labeled with Alexa Flour 647) were plated in adjacent chamber (0.5mm 
separation) of the cell culture insert at a density of 7500 cells/well. The cells were left overnight 
to attach and the following day the cell culture insert was removed to create a well-defined gap 
of 500 µm. The movement of the cells was captured every hour for 48 hours using a live cell 
imaging system. ImageJ software was used to track the individual cells for and analyzed using 
the plugin manual tracking and chemotaxis. 
 
In-vitro cell toxicity of MSC-Sph-NP  
 
The MSC-Sph-NP was prepared using MSC-TRAIL cells and NP loaded with the drug [MTX] 
at a concentration of 6µM using the previously described conditions. After the formation of the 
spheroids the double emulsion was broken and the spheroid was released. 20 µl of the spheroid 
was added to 20 µl of trypsin and was incubated at 37oC for 5 mins. The solution was vigorously 
pipetted up and down to break the spheroids. The number of cells was counted using a standard 
cell counter. The spheroids were seeded in a 24 well plate at different densities (20k, 15k, 10k, 
5k per well). 24 hours after plating the spheroids the cancer cells transduced with luciferase (5k 
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cells/well) was added to the spheroids containing plate. The cancer cells were co-cultured with 
the spheroids for 24 hours. Following this the Steady GLO substrate was added to the cells. The 
amount of luciferase substrate was measured using a plate reader to measure the luciferase 
signal. The amount of cell death was then calculated by assuming 100% viability in the case of 
cancer cells incubated with MSC not containing TRAIL and MTX. 
 
In-vivo retention and migration of MSC-Sph-NP  
 
U87MG cells (0.5*106 cell/ mice) were harvested at 80% confluency and injected 
subcutaneously into the nude mice (NU/J, Jackson Laboratory). The tumor formed within two 
weeks. 
a.   Cell retention 
MSC transduced with EGFP was used with NP labeled with Alexa Flour 680 to form MSC-NP 
Spheroids. 24 hours after the encapsulation of the cells in the double emulsion, the spheroids 
were released. The spheroids (300,000 cells/mice) were then injected into the mice at the edge 
of the tumor. Same amount of MSC in single cell format was mixed with the nanoparticles and 
injected in another set of the mice In vivo imaging system (IVIS, PerkinElmer) was used to take 
images of the mice with the GFP filter for MSC, cy5.5 for the NP and RFP for the cancer cells. 
Four days and seven days after the injection half of the mice for each condition was sacrificed 
and the individual organs were imaged. 
a.   Cell migration  
MSC transduced with luciferase was used with NP labeled with Alexa Flour 680 to form MSC-
NP Spheroids. Following the formation of the spheroids the double emulsion was broken and 
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the spheroids were released. The spheroids (250,000 cells/mice) were then injected into the 
mice at the edge of the tumor. Same amount of MSC in single cell format was mixed with the 
nanoparticles and injected into the other half of the mice. In vivo imaging system (IVIS, 
PerkinElmer) was used to take images of the position of MSC, NP and cancer. To image the 
MSC D-Luciferin (Rediject, PerkinElmer) was injected into the peritoneal cavity of the mice 
and imaged using the luciferase filter. The nanoparticles and the cancer cells were imaged using 
the cy5.5 and RF filters respectively. 21 days following the injection the mice were sacrificed 











































In-vivo subcutaneous tumor model 
 
The tumor was generated as mentioned previously. MSC transduced with TRAIL was used with 
NP containing MTX to form MSC-NP Spheroids. Following the formation of the spheroids the 
double emulsion was broken and the spheroids were released. The spheroids (250,000 
cells/mice) were then injected into the mice at the edge of the tumor. Same amount of MSC in 
single cell format was mixed with the nanoparticles and injected into the other half of the mice. 
The injection of the cells was performed on Day 0 and Day 2. The size of the tumor was then 





The data in the figures are represented by mean and standard error of mean. One-way analysis 
of variance (ANOVA) with the Tukey significant difference post hoc test was performed when 
more than two means were compared. T-test was performed when comparing two means. A 









3.3. Results and Discussion 
 
Need for co-delivery 
 
TRAIL and MTX were tested against multiple GBM cell lines (U87, T98G, LN229, LN18) and 
MSC. TRAIL was found to be resistant against U87MG and T98G while, MTX was found to 
be resistant against T98G and LN229. For the cell lines, U87MG and T98G we were not able 
to detect the IC50 value against trail up to concentrations of 100 nM (Figure 22). Taken 
together, this emphasizes the need for co-delivery of drugs to overcome resistance in cancer 
cells. The combination of MTX and TRAIL increased the apoptosis and even reversed the 
resistance in certain cell lines. Under MTX alone the cell viability of T98G was 103.78% while 
a combination of MTX and TRAIL decreased the cell viability to 20.78%. Similarly, for 
U87MG the cell viability changed from 59.72% to 7.99%, LN18 from 70.60% to 19.67% and 
LN229 from 63.51% to 40.50% (Figure 24). This clearly demonstrates the synergistic effect of 
using a combination of TRAIL and MTX a result of targeting both the intrinsic and extrinsic 
pathways simultaneously. Combination of TRAIL and MTX causes apoptosis through both p53 
independent and dependent pathways leading to increased apoptosis.  
 
MSC however, was found to be resistant under TRAIL treatment which could be attributed to 
the absence of any death receptors on its surface. Interestingly MTX and a combination of 
TRAIL and MTX also did not affect the viability of MSC. High cell viability of MSC could be 
a result of overexpression of the ATP binding cassette (ABC) transporters which are crucial to 
the maintenance of stemness 54. P-glycoprotein is a subfamily of the ABC transporters that 
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mediates drug efflux, which might be keeping the cell viability high 138 139 140. MTX is also cell 
cycle dependent and induces cell-cycle arrest in the G2/M phase, however, since a large 
population of MSC remains in the Go/G1 phase there is negligible response at high 
concentrations of MTX 141. Treatment using the combination of drugs led to more than 75% 
cell viability of MSC while less than 40% viability of the cancer cells. This shows that the 
combination of drugs used will not be toxic to the drug carrier MSC, but can cause toxicity in 
the cancer cells due to the large therapeutic window of treatment. The resistance of MSC to the 
















































Nanoparticle design and characterization 
 
The DNA-structured NP is formed via CaP nanoprecipitation (Figure 25A). NP forms through 
the interaction between phosphate backbone of the PEG-DNA and Ca2+ ions in the solution, 
and the PEG part confines the precipitation. The NP generated by this method is therefore size-
controllable and uniform. Also, controllable surface ligand density is another advantage of this 
method, which can be realized by mixing ligand-conjugated PEG-DNA and unmodified PEG-
DNA in a designated ratio. As shown in Figure B, without PEG, the generated NPs aggregated 
immediately right after incubated with Ca2+ buffer. In contrast, PEGylation enabled nano-sized, 
monodispersed NP generation. Zhang et al., showed that long PEG offered stronger steric 
repulsion, which benefited the colloidal stability, and the particle generated with 12-15kD of 
PEG was much more stable, compared with the one with short PEG (<5 kD) 132. Because of this 
and the prevention of undesired MSC uptake, we tested the combinations of two PEG (10 or 20 
kD) and two DNA lengths (20 or 40 mer). Longer PEG (20 kD) did not enlarge the particle size 
significantly when with the shorter DNA (20 mer) nor improve the stability in buffer, while it 
benefited the particle stability when with the longer DNA (PDI reduced from 0.12 to 0.06). 
Furthermore, with longer PEG, there was no difference in size and stability between two 
different DNA lengths. As a result, we chose longer PEG and DNA for the following 
experiments. Next, we used a florescent anthracenedione drug, bisantrene, as a model 
compound to verify if our approach had better loading efficiency and loading level. The loading 
efficiency reached nearly 100% when the DNA/drug ratio is close to 10, whereas the maximum 
loading level (~20%) was observed when the DNA/drug ratio is 0.02 (Figure 25C). Compared 
with other NP formulations, the loading level of our DNA-structured NP provides is at least 2.5 
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to 7 times higher 142.Figure 25D presents TEM images the inner crystalline CaP-DNA core of 
our DNA-structured NPs. The core size of the NP was ~20 nm in diameter, which was smaller 
than that of the similar system with PEG-dsRNA (~35 nm) 132 143. Compared with that system, 
the particle here was formed with ssDNA, which would be more flexible and may result in a 
more compact inner core after the precipitation.        
 
To increase the targeting capability of the nanoparticle system, IL13RA2 peptide which is found 
predominantly on the surface of the cancer cells was used to decorate the nanoparticle surface. 
The surface density of the cancer cells for IL13RA2 expression was measured using both qRT-
PCR and flow cytometry using anti-IL13RA2 antibody (Figure 26). U87 cell line was shown to 
have the highest expression, followed by LN18 and LN229. The presence of IL13RA2 peptide 



















Figure	  25.	  Characterization	  of	   the	  nanoparticle	   (A)	  Schematic	  of	  nanoparticle	   formation	   (B)	  
Average	  size	  distribution	  and	  PDI	  of	  the	  nanoparticle	  (C)	  Loading	  efficiency	  of	  the	  nanoparticle	  



















Figure	  26.	  Characterization	  of	  IL13RA2	  protein	  marker	  expression	  on	  the	  surface	  of	  the	  cancer	  















Generation and characterization of MSC-Sph-NP 
 
MSC spheroids encapsulating nanoparticle (MSC-Sph-NP) was prepared by mixing the MSC 
and nanoparticle before injecting them into the microfluidic platform. Like the previous 
formations, the MSC-Sph-NP was formed within the first four hours of incubation (Figure 
27A). Microfluidic platform allows for the encapsulation of the nanoparticle within the 
spheroids. Traditional platforms such as hanging drop, low attachment plates, membrane based 
aggregation, forced aggregation using centrifugation do not offer the confinement and uniform 
flow that allows for this type of encapsulation. The short incubation time is also advantageous 
due to the reduced contact time with the chemotherapeutic drug. 
 
MSC-Sph-NP prepared using MSC cells transduced with TRAIL and NP loaded with MTX, 
analyzed under flow cytometry showed more than 75% viability (Figure 27B). To visualize the 
MSC-NP-Sph, we labeled the cell membrane of MSC using PKH67 (green) and the nanoparticle 
using AF647 (Red). The MSC-Sph-NP was visualized under confocal microscope (Figure 27C). 
Most of the nanoparticle co-localized with the membrane of MSC (yellow). This demonstrates 
that the spheroid can carry both the drugs successfully without affecting its viability or the 
structural integrity. 
 
To investigate the distribution of MSC we designed the nanoparticle with both FITC and Alexa 
Flour 647 fluorescence. When the nanoparticle is in-tact they give out red fluoresce due to the 
self-quenching effect, and on breakdown following endocytosis they exhibit both green and red 
fluorescence due to the release of FITC-DNA part. Under flow cytometry the single cells 
87	  
	  
showed that 92.55% of the MSC were associated with NPs, and the majority of those MSC-
associated NPs remained intact (91.4%). Although in the case of spheroids, an enhancement of 
cell uptake was observed (47.9% vs. 1.15% in 2D), more than 50% were still stable and possibly 



















Figure	  27.	  (A)	  Formation	  of	  MSC	  Spheroid	  (green)	  encapsulating	  nanoparticles	  (red)	  within	  a	  
double	  emulsion	  (B)	  Cell	  viability	  of	  MSC	  spheroid	  carrying	  the	  nanoparticle	  (C)	  Confocal	  image	  
of	   nanoparticle	   (red)	   distribution	   in	   MSC	   spheroid(green)	   (D)	   Analysis	   of	   distribution	   of	  
nanoparticles	  analyzed	  using	  flow	  cytometry. 
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Migration of MSC-Sph-NP towards cancer cells 
 
The distinguishing feature of the system is the unique tumor trophic nature of MSC towards to 
cancer cells. To investigate if the MSC-Sph-NP can carry the nanoparticles to the tumor site we 
plated the MSC-Sph-NP and U87MG with a 500µm gap between them. The MSC was 
genetically engineered with the green fluorescent protein (GFP), nanoparticles were decorated 
with Alexa flour 647 (Far red) and the cancer cell U87MG was genetically engineered with red 
fluorescent protein (RFP) to visualize the movements. The cells were followed for 24 hours 
using live cell imaging and analyzed using the plugin manual tracking and chemotaxis tool 
(Figure 28A, Figure 28B). The MSC successfully carried the nanoparticles to the tumor cell 
vicinity as visualized by the co-localization of MSC (green) and nanoparticle (red) in the tumor 
vicinity (blue). There was no significant different between MSC-Sph with and without the 
nanoparticle analyzed through the various parameters assessed including velocity (Figure 28C), 











Figure	  28.	  Migration	  of	  MSC	  Spheroids	  (green)	  carrying	  nanoparticle	  (red)	  towards	  cancer	  cell	  
(blue)	  at	  (A)	  time	  0	  (B)	  time	  24	  hours	  (C)	  Analysis	  of	  velocity	  of	  cells	  (D)	  Directionality	  which	  is	  
the	  accumulated	  distance	  divided	  by	  the	  Euclidian	  distance	  (E)	  Euclidian	  distant	  (F)	  Tracking	  of	  































































In-vitro toxicity of MSC-Sph-NP  
 
To investigate the in-vitro killing effect of the system, MSC-Sph-NP was co-cultured with three 
different GBM cell types, U87, LN18, and GBM8. All three cell types saw a dose dependent 
killing when co-cultured with MSC-NP-Sph. When co-cultured with MSC-Sph only 68% of 
U87MG and 1.14% of GBM8 cells survived, however, in the presence of MSC-Sph-MTX it 
dropped to 51% and 0.41% (Figure 29). This shows the synergistic effect due to the co-delivery 
of TRAIL and MTX. U87MG and GBM8 when co-cultured with MSC-Sph-NP dropped even 
further down to 34% and 0.4%. This significant drop could be a result of lower toxicity to the 
MSC cells because the MTX is shielded by the nanoparticle. Another reason could be the 
increased uptake of MTX-NP by the cancer cells due to the pep-1 targeting effect. In fact, 
U98MG and GBM8 highly expresses the IL13RA2 receptor which binds to the pep-1 targeting 
ligand, while, LN18 does not express the ligand. The poor expression of IL13RA2 in the surface 



















Figure	  29.	  Figure	  23.	  In-­‐vitro	  toxicity	  of	  MSC-­‐Sph-­‐NP	  against	  three	  different	  glioma	  cell	  lines	  











In vivo retention and migration of MSC-Sph-NP 
 
To test the in-vivo retention and migration of the system, we injected the mouse sub-cutaneous 
with U87. The tumor formed within two weeks. Following this either single cells and 
nanoparticle or MSC-Sph-NP was injected at the edge of the tumor. The MSC was genetically 
engineered to produce GFP (green), U87 was engineered to produce RFP (red) and the 
nanoparticle was labeled with Alexa flour 680 (far red). Using a fluorescence imaging system, 
the three components was tracked every other day. Half the mice were sacrificed on day 4 and 
the rest of day 7. The organs were then individually imaged. On day 4 the signal from both 
single and spheroids was seen co-localized with the tumor. However, on day 7 only the signal 
from spheroids was visualized (Figure 30). This could imply higher retention of the spheroids 
compared to the single cells. The presence of ECM could help with the engraftment of the cells, 
spheroids activate pro-survival signal under hypoxic condition and finally the increased 
expression of CXCR4 in the spheroids could lead to faster migration. Collectively, these factors 
could help spheroids last longer at the tumor site. 
 
The experiment was repeated to track the co-localization of the nanoparticle and cell signal by 
imaging every other day. In the case of MSC-Sph-NP there was high retention and co-
localization of the signal with MSC and tumor (Figure 31). This shows that the MSC-Sph can 
carry the nanoparticle to the tumor with high efficiency. The single cell group on the other hand 
did not show any signal from the nanoparticle by day 8. The simultaneous delivery of the drugs 
preferable to the same cells is highly crucial for efficient co-delivery therapy. In this sense 






Figure	  30.	  Figure	  25.	  Ex-­‐vivo	  image	  of	  organs	  of	  the	  mice	  sacrificed	  on	  day	  4	  and	  day	  7	  after	  














Figure	  31.	  In-­‐vivo	  image	  of	  MSC-­‐NP-­‐Sph	  (MSC-­‐Green,	  Nanoparticle-­‐Red)	  and	  single	  cells	  with	  







In vivo therapeutic efficacy of MSC-Sph-NP 
 
To investigate the therapeutic efficacy of the system the mouse was injected with U87 cells 
subcutaneously. Following the tumor formation two doses of MSC-Sph-NP or Single MSC-NP 
was injected at the edge of the tumor on Day 1 and Day 3. The volume of tumor was then 
tracked for 21 days (Figure 32A). The MSC-Sph-NP group showed significantly smaller 
increase tumor volume compared to the Single MSC-NP and PBS group (Figure 32B). The 
weight of the tumor on day 21 was 0.053g compared to 0.13g in the single cells and nanoparticle 
group and 0.36g in the PBS control group. This could be a direct result of increased retention 
of the spheroids and nanoparticle at the tumor site as seen previously. The mice did not show 
any immunotoxicity to MSC, NP, MTX or TRAIL this was seen in the constant spleen length 
between all the groups, 15.82mm in the spheroid group. 15.6mm in the single cell group and 
15.83mm in the control PBS group (Figure 32C) 144. The volume of the tumor however, started 
to show an upward trend after 21days which could be a result of MSC cell death. In the future, 












Figure	   32.	   (A)	   Tumor	   volume	   change	   over	   time	   for	  MSC-­‐NP-­‐SPh,	   Single	  MSC+NP,	   and	   PBS	  
cpntrol	  group	  (B)	  Tumor	  sizes	  after	  day	  21	  (C)	  Tumor	  volume	  at	  the	  end	  of	  day	  21	  and	  spleen	  






The ability to deliver multiple therapeutics is crucial to the future of cancer therapy. It is highly 
unlikely that just one drug would be able to treat cancer. MSC-Sph-NP can carry and deliver 
two different types of drugs. The nanoparticle is well distributed within the spheroids and the 
spheroids were shown to be able to carry the nanoparticle to the tumor site. Co-delivery of drugs 
by MSC-NP-Sph led to higher killing of cancer cells in-vitro. The MSC-Sph-NP also led to 
higher retention of cells and nanoparticles at the site of the tumor compared to just single cells 
and nanoparticle. These two factors translated to smaller tumor volume increase and better 
















Chapter 4. Graphene oxide cellular patches for 




An effective cancer therapy would discern cancer cells from normal cells and allow for robust 
killing of the cancer cells only. However most anti-tumor drugs are not specific and 
indiscriminately kill the cells around them. Targeted delivery of these drugs using nanoparticles 
have also not been successful because of masking of the targeting ligands by the biological 
components. Survey of the literature for the past 10 years has shown that only 0.7% (median) 
of the injected nanoparticles penetrate the tumor5.  
 
Thus, there is a need to develop a more effective drug delivery system that will allow for 
targeted killing of cancer cells.  
  
Modified graphene oxide (GO), a 2D graphene sheet functionalized with carboxylic acid, 
epoxide and hydroxyl group has been successfully used in various biomedical applications 
including bio imaging, gene delivery, drug delivery and tissue engineering57. The high specific 
surface area allows for high drug loading though π-π stacking, electrostatic or hydrophobic 
interaction with small molecules, proteins, and nucleic acid. Sun et al have shown high loading 
of DOX on graphene via adsorption and pH dependent-release145. Since the tumor 
microenvironment is acidic this allows for site-specific release of the drug. While graphene 
oxide is a versatile platform to deliver a wide range of therapeutics with controlled release, the 
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low accumulation of graphene oxide at the tumor site is of serious concern for effective 
translation of this technology59,60. 
 
Mesenchymal stem cells (MSC) on the other hand have inherent tumor trophic property making 
it an attractive candidate for cancer therapy7. The site-specific delivery of chemotherapeutics 
ensures minimal off-target effects, while immune compatibility allows for allogeneic 
transplantation. It has additional advantages: it is deemed to be safe as reported by more than 
350 clinical trials, it is easily isolated from a wide range of sources and it allows for facile 
genetic manipulation.  Collectively these factors make MSC an ideal carrier for cancer 
therapy146. 
 
Therapies using MSC, however, have been limited to genetically engineering the cells to secrete 
anti-tumor peptidic drugs. Various strategies have been used for targeted treatment of different 
cancer types such as delivery of (1) interleukins to regulate the inflammatory and immune 
response15, (2) interferons to inhibit tumor growth17, (3) enzymes to activate prodrug147, and (4) 
pro- apoptotic proteins such as TRAIL to inhibit cancer cell proliferation61. This however, 
precludes the delivery of non-peptidic drugs and therapeutic nucleic acids that can combat 
tumor progression via different mechanisms. Cancer is highly heterogeneous in nature and is 
constantly evolving. It is highly unlikely that any one anti-tumor drug would be successful. 




































Drug-loaded NP are usually coupled with MSC therapy through either cellular 
internalization108,148,149 150 or surface anchorage54. In case of cellular internalization, the loading 
efficiency depends on a plethora of particle characteristics such as charge, hydrophobicity, size 
and shape. The stability and availability of the drug internalized by the MSC depends on the 
drug’s ability to escape the late endosome, and the effects of the drug within MSC are of 
concern. In case of surface anchorage, the interaction might be short-lived depending on the 
specific receptor to which they bind. The cell also has the potential to turn immunogenic after 
engineering due to the alteration in membrane composition151. These methods release the drugs 
through either exocytosis or simple diffusion making it harder to control and predict the release. 
There is also a high possibility that the cells would excrete the drugs before reaching the target 
site. Hence, there is a need to develop a system that is capable of controlled delivery of a wide 
variety of drugs while taking advantage of MSC’s tumor trophic properties for targeted delivery. 
 
We propose to combine the drug delivery capability and the cellular interaction of GO to load 
drugs onto the surface of MSC (Figure 33). On one hand, the graphene oxide flakes allow for 
cellular interaction mediated by the hydrophobic interactions, electrostatic forces and hydrogen 
bonding between the GO and proteins from the cell culture media152, versatility for adsorbing a 
wide range of therapeutics, and minimal internalization into MSC. On the other hand, the tumor-
trophic MSC can carry the drug-loaded GO adsorbed on the cell surface to the tumor site and 





To test the hypothesis, we used doxorubicin hydrochloride (DOX) and mitoxantrone (MTX) as 
model drugs adsorbed on GO through physical mixing. The GO-loaded MSC was then tested 























4.2 Materials and Methods 
 
 
Making GO-Drug complex 
 
GO used in all the experiments were bought from Graphene Supermarket. The GO used was 
5mg/mL and the size of the flakes ranged from 1-6 µm. To prepare GO-Drug, GO was sonicated 
and mixed with different ratio of the drugs: DOX, and MTX (Sigma). The complex was left in 




Table	  1.	  Concentration	  of	  GO,	  DOX/MTX	  and	  water	  used	  to	  load	  drugs	  on	  the	  surface	  of	  GO	  
Sample GO Volume (5 mg/mL) µL DOX/MTX Volume (1 mg/mL) 
µL 
Water (µL) 
1 7.25 2.5 500 
2 7.25 5 500 
3 7.25 7.5 500 
4 7.25 10 500 
5 7.25 12.5 500 
 




To measure the loading of the drugs on GO. The supernatant from the wash steps was collected.  
The absorbance of DOX at 478nm and MTX at 610nm in the supernatant was used to measure 
the amount of drug loaded onto GO. The following equation was used to measure the loading 
of the drug on GO.  
Loading (mg of drug/mg of GO) =!"#$%	   '()* +,-.	   /0 1+2-23$4,+%$#-.	  ['()*]	  (/0)!"#$%	  $/"+2#	  "9	  *:	  (/0)  
 
Release of DOX and MTX from Graphene oxide 
 
GO-DOX and GO-MTX at the highest loading level was prepared and added to the dialysis bag 
with a molecular weight cut off 1000 Da. Half the dialysis bags were suspended in 5 mL of PBS 
at pH7.4 and the rest at PBS at pH5.5. Samples were collected at regular interval. To increase 
the concentration of the drug in the solution the collected sample was freeze dried and 
resuspended in a smaller volume of PBS to increase the concentration 25-fold. The amount of 
drug released was then measured using absorbance plate reader at 478nm for DOX and 610nm 
for MTX.  
 
GO-DOX and GO-MTX toxicity of cells 
 
To understand the effect of GO-Drug on the cells, MTT (3-(4, 5-dimethylthiazolyl-2)-2, 5-
diphenyltetrazolium bromide) assay was performed. Briefly, the cells were plated in a 96 well 
and exposed to a rage of concentrations of either GO, GO-DOX, or GO-MTX. After 24 hours, 
the MTT reagent was added and the cells were incubated at 37oC for 2 hours before measuring 
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the absorbance at 570nm using a plate reader. The cell viability was calculated by comparing 
to untreated cells which was assumed to be 100% viable. 
Formation of MSC-GO 
 
The MSC and GO were incubated for 4 hours at 37oC, 5% CO2 and 95% relative humidity to 
allow the GO to adhere to MSC. Following this the cells were washed twice, trypsinized and 
re-plated in a new plate and cultured for further experiments.  
 
Scanning Electron Microscope 
 
MSC-GO complex was also analyzed using a Zeiss SIGMA VP scanning electron microscope 
(SEM) operated at 5.00 Kv. For this the cells were first fixed with 4% paraformaldehyde. 
Dehydration of the fixed cells was carried out sequentially using ethanol of concentration 30%, 
50%, 70%, 90% and 100%. The sample was then washed thrice with Hexamethyldisilazane 
(Sigma) and allowed to dry at room temperature and coated with gold in sputter coater before 




To visualize the interaction of MSC and GO, GO was labeled with Dil (1µg/mL, 
Thermoscientific) overnight at 37oC 152. The complex was washed thrice with PBS to remove 
the unbound dye. This complex at concentration of 10ug/mL of GO was used to bind to MSC. 
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After binding the cells were trypsinized and analyzed using fluorescence microscopy (Nikon 




To understand the effect of GO on the cells, MTT (3-(4, 5-dimethylthiazolyl-2)-2, 5-
diphenyltetrazolium bromide) assay was performed. Briefly, MSC were plated in a 96 well and 
exposed to a rage of concentrations of either GO. After 1,3, and 5 days, the MTT reagent was 
added and the cells were incubated at 37oC for 2 hours before measuring the absorbance at 
570nm using a plate reader. The cell viability was calculated by comparing to untreated cells 




Migration assay was performed using the two-chamber cell culture insert (ibidi). The cancer 
cell LN18 expressing mcherry and MSC-GO-Drug (0, 2.5 µg/mL, 5 µg/mL, and 10 µg/mL) 
were plated in adjacent chamber (0.5mm separation) of the cell culture insert at a density of 
7500 cells/well. The cells were left overnight to attach and the next day the cell culture insert 
was removed to create a well-defined gap of 500 µm. The movement of the cells were then 
captured every hour for 48 hours using a live cell imaging system. ImageJ software was used 







MSC is loaded with GO-DOX or GO-MTX and incubated for 4hrs. The cells are trypsinized 
and replated in a 96 well plate at different cell densities (20k, 15k, 10k, 5k, 0.5k). The cells are 
allowed to attach to the plate for 24 hrs. The cancer cells (5k, U87 and GBM8) are then added 
to the plate and incubated for an additional 24 hrs. The number of cancer cells is then counted 
using the luciferase reagent (Steady GLO, Promega) which measure the amount of luciferase in 
the solution through a plate reader. Since there is a strong and direct correlation between the 





MSC is loaded with GO-DOX and GO-MTX and incubated for 4hrs. The cells are trypsinized 
and added to the cell culture insert (7.5k) along with the cancer cell (LN18 in the other 
chamber). The cells are allowed to attach to the plate for 24 hrs. The cell culture insert is 
removed and the cells are tracked for 24 hours using a live cell microscope. After 24 hours, the 
number of cancer cell death is measured using the luciferase agent (Steady GLO, Promega) and 






MSC is loaded with GO-DOX and GO-MTX and incubated for 4hrs. The cells are trypsinized 
and plated in the top chamber of the cell culture insert and incubated for 24hrs. Following this 
the cancer cells are plated in the lower chamber and incubated for 24 hrs. The amount of cancer 
cells killed is then measured using luciferase reagent (Steady Glow Promega) and the plate 
reader.  
 
MSC-GO and TRAIL 
 
MSC was transduced to produce TRAIL using the previously mentioned protocol. The MSC-




The data in the figures are represented by mean and standard error of mean. One-way analysis 
of variance (ANOVA) with the Tukey significant difference post hoc test was performed when 
more than two means were compared. T-test was performed when comparing two means. A 









4.3 Results and Discussion 
 
Loading and Release of graphene oxide 
 
The large surface area of GO makes it an excellent candidate to load a wide range of 
therapeutics. The drug loading level increased with the ratio of drug:GO in the solution. At 0.5 
mg/mL of drug the DOX loading capacity was 0.34 mg of DOX per mg of GO, and the MTX 
loading capacity was 0.35 mg of MTX/mg of GO (Figure 35A). The interaction between GO 
and the drug is mostly governed by the π-π stacking as well as hydrogen bonding between the 
–OH and –COOH on GO and –OH and –NH2 on DOX 153. In case of the release (Figures 35B 
and C) for both DOX and MTX we can see a burst release within the first 20 hours. However, 
since most of the drugs are released within the first three days this could potentially limit the 
ability to target invasive glioblastoma cells that have spread to the contra-lateral hemisphere. 
Additionally, in case of both drugs double the amount of drug was released at the lower pH of 
5.5 (29% DOX, 40% MTX) compared with the normal physiological pH of 7.4 (15% DOX, 
20%MTX). This could be due to the partial dissociation of hydrogen bonding at low pH leading 
to the release of the drugs. This would be useful because the pH surrounding the cancer cells 
would be lower than the physiological pH 154, which could trigger the release of the drug from 
GO. This could possibly be a secondary level of targeting to release the drugs close to the site 












Figure	   34.	   Characterization	   of	   Graphene	  Oxide	   (A)	   Fourier-­‐transform	   infrared	   spectroscopy	  
profile	  (B)	  Ultraviolent-­‐visible	  spectroscopy	  spectrum	  (C)	  Scanning	  electron	  microscope	  image	  




















Figure	  35.	  Characterization	  of	  GO-­‐DOX	  and	  GO-­‐MTX	  complex	  (A)	  Loading	  of	  DOX	  and	  MTX	  on	  GO	  
at	  different	  initial	  concentrations	  (B)	  Cumulative	  release	  of	  DOX	  at	  pH	  5.5	  and	  pH	  7.4	  (C)	  
Cumulative	  release	  of	  MTX	  at	  pH	  5.5	  and	  pH	  7.4.	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MSC-GO loading and characterization 
 
To understand the long-term toxicity of GO on MSC, the cells were incubated with increasing 
concentrations of GO ranging from 0.2µg/mL to 100µg/mL for 1,3 and 5 days. At the end of 
each time point MTT assay showed that the cell viability was above 80% for GO concentrations 
up to 100µg/mL (Figure 36C).  Although GO quenches fluorescence signal, we used previously 
published protocol of using high concentrations of Di-l to overcome this issue. The fluorescent 
image of the MSC-GO shows that the GO is localized on the surface of MSC (Figure 36A). The 
size of the particle is known to affect the cellular uptake efficiency. While most studies have 
shown uptake of GO using nanographene oxide (20-300nm), we used larger flakes (1-6 µm) 
which are not easily internalized by MSC. The interaction between the cells and GO is probably 
aided by the extracellular matrix (ECM) adsorption on the surface of GO via hydrophobic, 
electrostatic, and hydrogen bonding. Flow cytometry analysis showed that more than 95% of 
the cells were associated with GO (Figure 36B), further demonstrating the efficient interaction 
between GO and MSC. SEM analysis further confirmed that the GO remained attached to the 








































Figure	  36.	  Characterization	  of	  MSC-­‐GO	  complex	  (A)	  Fluorescent	  image	  of	  MSC	  (green)	  and	  GO	  
(red)	  (B)	  Flow	  cytometry	  analysis	  of	  MSC	  and	  MSC-­‐GO	  (C)	  Cell	  viability	  of	  MSC	  across	  a	  range	  of	  
GO	  concentrations	  for	  Day	  1,	  3	  and	  5	  (D)	  SEM	  image	  of	  MSC-­‐GO	  complex.	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GO-Drug toxicity characterization 
 
The ability of MSC to carry GO-Drug hinges on its ability to survive at concentrations that are 
toxic to the cancer cells. Avoiding cellular damages is crucial for effective delivery. GO loaded 
with DOX and MTX were added to MSC as well as a range of cancer cells (LN18, GBM8, 
MDA-MB-231) to evaluate the toxicity. LN18 is a human glioblastoma cell line, GBM8 is a 
patient derived human glioblastoma cell line, and MDA-MB-231 is a human breast 
adenocarcinoma cell line. At concentrations of 5µg/mL of GO-MTX, 87% of MSC survived 
while only 12% of Hela, 28% of LN18, 21% of GBM8, and 37% of MDA-MB-231 survived 
(Figure 37). This wide gap in toxicity has been reported previously and attributed to possible 
drug-resistant ability of MSC150. This indicates that we can load GO-Drug on to MSC at 
concentrations that are not toxic to MSC but can still effectively kill the cancer cells. The largest 


































Figure	  37.	  (A)	  Cell	  viability	  of	  cancer	  cells	  across	  a	  range	  of	  GO-­‐DOX	  concentrations	  (B)	  Cell	  
viability	  of	  cancer	  cells	  across	  a	  range	  of	  GO-­‐MTX	  concentrations.	  Data	  are	  presented	  as	  
average	   	  standard	  error	  of	  mean	  (n	  =	  3).	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Migration of MSC-GO towards cancer cells 
 
To understand the effect of GO on the migration potential of MSC, different concentrations of 
GO (0, 2.5 µg/mL, 5 µg/mL, and 10 µg/mL) was loaded on to MSC and its migration towards 
cancer cells were analyzed. Using manual tracking and chemotaxis we analyzed various 
parameters such as distance travelled, velocity, directionality. MSC without cancer cells moved 
significantly slower and had lower directionality. The Rayleigh test for MSC without and with 
cancer cells had p-value of 0.277 and 2.16*10^-7 further demonstrating that the cancer cells are 
required for directional movement of MSC. The migration of MSC characterized by the velocity 
and directionality was not affected by the presence of GO. Irrespective of the concentration of 
GO the MSC-GO complex can migrate towards the tumor cells with a high degree of 
directionality (Figure 38). While the mechanism for the migration of MSC towards cancer cells 
is still under investigation the most popular hypothesis is the interaction of the C-X-C 
chemokine receptor type 4 (CXCR-4) from MSC towards the SDF-1 gradient created by the 
cancer cells155. On analyzing the CXCR4 levels of MSC coated with different concentrations 
of GO we found a two-fold increase, confirming the results that the migration is not affected by 




















Figure	  38.	  Effect	  of	  GO	  on	  migration	  of	  MSC	  (A)	  Live	  cell	  image	  of	  MSC-­‐GO	  (GO	  is	  green)	  moving	  
towards	  LN18	  (Red)	  at	  time	  0	  hours	  and	  24	  hours	  (B)	  Velocity	  of	  the	  cells	  under	  different	  GO	  
concentrations	   (C)	  Directionality	   is	   the	   ratio	  of	   the	  euclidian	  distance	  and	   the	  accumulated	  








In-vitro toxicity of MSC-GO-Drug 
 
LN18 was cultured with MSC-GO-Drug and in case of both DOX and MTX the cancer cells 
were killed in a dose-dependent manner. At the ratio of 2:1 (MSC: cancer cells), the amount of 
LN18 that survived was 46%. To test our hypothesis that the MSC-GO-Drug needs to carry the 
drug and migrate towards the cancer cells to kill it, we used three different models: Co-culture, 
Migration and Transwell. In case of the transwell model, the MSC and cancer cells have a 
barrier in between hence only the drug that has been released from GO can diffuse and kill the 
cancer cells. In the migration model the MSC needs to carry the GO-Drug to the cancer cells 
500um apart to kill them. Finally, in the third co-culture model the cells and the cancer cells are 
co-cultured so the killing is done through cell-cell contact. The co-culture model had the highest 
cell death (54%) followed by the migration model (53%) and finally the transwell model (27%). 
This shows that the drug does not easily detach from the complex, but rather needs to be carried 
by MSC towards the cancer cells for effective killing. This again would raise the cancer-cell 
specificity of this delivery system. 
 
In-vitro toxicity of MSC-TRAIL-GO-Drug 
 
While MSC-GO is an effective carrier for small molecules, it is not effective against all the cell 
lines. MSC-GO-DOX is unable to kill GBM8 due to low IC50 of DOX. Hence it is inevitable 
that we would need a combination of drugs to effectively translate this technology to all cancer 
types. For this we used MSC transduced with TRAIL to load GO-DOX. The combination of 
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Figure	  40.	  In	  vitro	  toxicity	  of	  (A)	  MSC-­‐GO	  co-­‐cultured	  with	  LN18	  (B)	  MSC-­‐GO	  co-­‐cultured	  with	  









Figure	  41.	  (A)	  Toxicity	  of	  MSC-­‐GO-­‐MTX	  against	  LN18	  in	  different	  in	  vitro	  models	  (B)	  	  Toxicity	  
of	  MSC-­‐TRAIL-­‐GO-­‐MTX	  against	  LN18	  in	  different	  in	  vitro	  model	  (C)	  Time	  delayed	  toxicity	  of	  
MSC-­‐GO-­‐MTX	  in	  the	  migration	  model	  (n	  =	  3;	  significance:	  **:	  p	  <	  0.01;	  n.s.:	  not	  significant;	  










This study shows that the MSC-GO is an effective vehicle to carry the drugs to the tumor cells. 
MSC-GO forms a strong bond which was visualized by fluorescence imaging, flow cytometry 
and SEM. The migration of this complex is not affected by the concentration of GO. MSC-GO-
Drug is also capable of killing the cancer cells in a dose-dependent manner. Finally, we could 
show that MSC-GO-Drug needs to be in cell-cell contact to be an effective system. This 
versatile system can be used to load a wide range of therapeutics and can be used as an effective 





















Cancer drugs while highly efficient in killing cells has a few disadvantages. (1) It is inefficient 
in discerning cancer cells from normal cells which, inevitably leading to numerous side effects  
(2) They have poor pharmacokinetic leading to short half-life, low accumulation at the tumor 
site, and inability to cross the blood brain barrier. (3) The constant evolution of the cancer cells 
makes it highly unlikely to be treated by any single cancer drugs, it is inevitable that a 
combination of drugs will be needed for efficient therapy. 
 
Stem cells such as mesenchymal stem cells and neural stem cells have proven to be superior 
alternative in treating hard to treat cancer types. They can migrate to the cancer cells with high 
efficiency, release drugs constantly at the tumor site and are relatively harmless to the 
neighboring cells. However, (1) poor retention and survival (2) inability to co-deliver multiple 
therapeutics (3) inability to deliver drugs that are not protein based are three main disadvantages 
of using the system.  
 
To solve these three issues, we engineered the MSC in multiple different ways. The MSC was 
engineered to form either multicellular spheroids or cell sheet to increase the cell retention and 
survival at the tumor site. The cell spheroids showed higher retention in the intracranial 
glioblastoma tumor model. However due to the small limit in the injection volume we were not 
able to show better therapeutic efficacy. To tackle the issue of co-delivery we used the MSC 
spheroids to encapsulate nanoparticles. The MSC was engineered to produce TRAIL and the 
nanoparticles were loaded with MTX. In a subcutaneous tumor model the MSC showed higher 
125	  
	  
retention at the tumor site. The co-deliver of MSC-Sph-NP also led to higher retention of 
nanoparticles at the tumor site. The combined effect of co-delivery, higher retention of MSC 
and nanoparticle translated to better therapeutic efficacy in a sub cutaneous tumor model. 
Finally, to engineer MSC to load drugs apart from peptidic based drugs we engineered the cells 
to load graphene oxide on the surface. Graphene oxide is a versatile platform that can carry a 
wide range of therapeutics ranging from small molecules, proteins, siRNA and DNA. MSC-GO 
successfully carried two different drug types DOX and MTX. We showed that MSC could carry 
the drugs to the cancer cells and lead to dose dependent killing of the cancer cells. 
 
In the future, we propose to test the three systems in an intracranial glioblastoma tumor model 
using human primary brain tumor cells. This will be a more relevant tumor model and accelerate 
the study towards clinical translation. Glioblastoma is one of the most aggressive forms of brain 
tumor with a very bleak chance of survival. Testing and proving the system in such a model 
would help push the technology to the clinics faster.  MSC engineered to produce cancer drugs 
are already in clinical trial to treat a wide range of cancer types. Hence it will be highly 
interesting to test the efficacy of our system to treat other cancer types such as pancreatic cancer, 
breast cancer and ovarian cancer. The system is easily translated to load a wide variety to drugs 
and malleable to treat other cancers. While we showed MSC-GO can carry DOX and MTX we 
would like to explore the ability of the system to carry protein, and DNA based drugs. This 
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